Patent Grant
9545523
The following commonly assigned U.S. patent applications and U.S. patents are incorporated herein by reference in their entirety:
U.S. Patent Publication No. 2008/0287839 entitled “METHOD OF ENHANCED REMOVAL OF HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS AND TREATMENT APPARATUS HAVING AN ACTUATOR”;
U.S. Pat. No. 6,032,675 entitled “FREEZING METHOD FOR CONTROLLED REMOVAL OF FATTY TISSUE BY LIPOSUCTION”;
U.S. Patent Publication No. 2007/0255362 entitled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Pat. No. 7,854,754 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Patent Publication No. 2011/0066216 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Patent Publication No. 2008/0077201 entitled “COOLING DEVICES WITH FLEXIBLE SENSORS”;
U.S. Patent Publication No. 2008/0077211 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE”;
U.S. Patent Publication No. 2009/0118722, filed Oct. 31, 2007, entitled “METHOD AND APPARATUS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS OR TISSUE”;
U.S. Patent Publication No. 2009/0018624 entitled “LIMITING USE OF DISPOSABLE SUBJECT 11 PROTECTION DEVICES”;
U.S. Patent Publication No. 2009/0018623 entitled “SYSTEM FOR TREATING LIPID-RICH REGIONS”;
U.S. Patent Publication No. 2009/0018625 entitled “MANAGING SYSTEM TEMPERATURE TO REMOVE HEAT FROM LIPID-RICH REGIONS”;
U.S. Patent Publication No. 2009/0018627 entitled “SECURE SYSTEM FOR REMOVING HEAT FROM LIPID-RICH REGIONS”;
U.S. Patent Publication No. 2009/0018626 entitled “USER INTERFACES FOR A SYSTEM THAT REMOVES HEAT FROM LIPID-RICH REGIONS”;
U.S. Pat. No. 6,041,787 entitled “USE OF CRYOPROTECTIVE AGENT COMPOUNDS DURING CRYOSURGERY”;
U.S. Pat. No. 8,285,390 entitled “MONITORING THE COOLING OF SUBCUTANEOUS LIPID-RICH CELLS, SUCH AS THE COOLING OF ADIPOSE TISSUE”;
U.S. Provisional Patent Application Ser. No. 60/941,567 entitled “METHODS, APPARATUSES AND SYSTEMS FOR COOLING THE SKIN AND SUBCUTANEOUS TISSUE”;
U.S. Pat. No. 8,275,442 entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS”;
U.S. patent application Ser. No. 12/275,002 entitled “APPARATUS WITH HYDROPHILIC RESERVOIRS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. patent application Ser. No. 12/275,014 entitled “APPARATUS WITH HYDROPHOBIC FILTERS FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Patent Publication No. 2010/0152824 entitled “SYSTEMS AND METHODS WITH INTERRUPT/RESUME CAPABILITIES FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Pat. No. 8,192,474 entitled “TISSUE TREATMENT METHODS”;
U.S. Patent Publication No. 2010/0280582 entitled “DEVICE, SYSTEM AND METHOD FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”;
U.S. Patent Publication No. 2012/0022518 entitled “COMBINED MODALITY TREATMENT SYSTEMS, METHODS AND APPARATUS FOR BODY CONTOURING APPLICATIONS”;
U.S. Publication No. 2011/0238050 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”;
U.S. Publication No. 2011/0238051 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”; and
U.S. Publication No. 2012/0239123 entitled “DEVICES, APPLICATION SYSTEMS AND METHODS WITH LOCALIZED HEAT FLUX ZONES FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”.
The present application relates generally to multi-modality treatment systems, methods and apparatus for altering tissue (e.g., subcutaneous lipid-rich tissue) including systems and methods for generating electrical fields and removing heat to affect targeted tissue. The present application also relates to temperature-controlled electroporation treatment systems and methods for altering targeted tissue.
Excess body fat, or adipose tissue, may be present in various locations of the body, including, for example, the thigh, buttocks, abdomen, knees, back, face, arms, and other areas. Excess adipose tissue can detract from personal appearance and athletic performance. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat lobules protrude or penetrate into the dermis and create dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be cosmetically unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat.
A variety of methods have been used to treat individuals having excess body fat and, in many instances, non-invasive removal of excess subcutaneous adipose tissue can eliminate unnecessary recovery time and discomfort associated with invasive procedures such as liposuction. Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting, or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body often cannot be achieved using general or systemic weight-loss methods.
Other methods designed to reduce subcutaneous adipose tissue include laser-assisted liposuction and mesotherapy. Newer non-invasive methods include applying radiant energy to subcutaneous lipid-rich cells via, e.g., radio frequency and/or light energy, such as described in U.S. Patent Publication No. 2006/0036300 and U.S. Pat. No. 5,143,063, or via, e.g., high intensity focused ultrasound (HIFU) radiation such as described in U.S. Pat. Nos. 7,258,674 and 7,347,855. Additional methods and devices for non-invasively reducing subcutaneous adipose tissue by cooling are disclosed in U.S. Pat. No. 7,367,341 entitled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al. and U.S. Patent Publication No. 2005/0251120 entitled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., the entire disclosures of which are incorporated herein by reference.
In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles may not be drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the drawings.
Systems, devices and methods are provided herein that enable simultaneous or sequential cooling and delivery of energy to a target region selectively to affect targeted cells. Several of the details set forth below are provided to describe the following examples and methods in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them. Several of the details and advantages described below, however, may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the claims but are not described in detail.
Reference throughout this specification to “one example,” “an example,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment,” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, stages, or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.
As used herein, the terms “bipolar” and “monopolar” can refer to an electrode configuration or in other embodiments to an electrical pulse, or pulse waveform. For example, a “bipolar electrode configuration” or “bipolar configuration” can refer to having two or more electrodes between which an electric field can be generated. In other embodiments, “bipolar” can refer to the waveform of an electrical signal generated and/or delivered to two or more electrodes, and such as described in U.S. Pat. No. 7,054,685, which is incorporated herein by reference in its entirety. Likewise, “monopolar electrode configuration” or monopolar configuration” can refer to having one or more electrodes that generate an electric field that can dissipate at a particular depth or distance away from the electrode(s). “Monopolar” can also refer to the electrical pulse or waveform generated and delivered to the electrode(s), such as described further in U.S. Pat. No. 7,054,685.
Some embodiments of the disclosure are directed to a system for affecting lipid-rich cells in a region of a human subject's body. The system can include a treatment unit configured to house a coolant. In one embodiment, the treatment unit can be in thermal communication with a fluid chamber for holding the coolant. The system can also include an energy generating unit, for example for generating electrical pulses, and an applicator in fluid communication with the treatment unit and in electrical communication with the energy generating unit. The system can further include a controller in communication with the treatment unit and the energy generating unit. In one embodiment, the controller has instructions for causing the applicator to reduce a temperature of (e.g., extract heat from) a target region beneath the epidermis of the subject to reduce a temperature of subcutaneous lipid-rich cells in the target region to a second temperature less than 37° C. After reducing the temperature of the target region, the instructions can cause the applicator to apply energy across the target region to form pores in membranes of the subcutaneous lipid-rich cells. In one embodiment, the instructions can cause the applicator to apply voltage across the target region to produce a pulsed electric field in an amount sufficient to form the pores.
Other aspects of the disclosure are directed toward a temperature-controlled electroporation treatment system for cosmetically altering a target region of a human subject's body to achieve a cosmetically beneficial alteration of tissue, such as subcutaneous adipose tissue. The temperature-controlled electroporation treatment system can include a treatment unit in thermal communication with a fluid chamber. The temperature-controlled electroporation treatment system can also include an electroporation energy source, a controller and an applicator. The applicator can include a first electrode and a second electrode in electrical communication with the electroporation energy source and a cooling element in communication with the treatment unit. In one embodiment, the controller includes instructions that cause the applicator to remove heat from the target region of the subject to reduce a natural body temperature to a lower temperature. The controller can also include instructions that cause the applicator to deliver an electric field through the target region such that subcutaneous lipid-rich cells at the target region are substantially affected while non-lipid-rich cells at the target region are not substantially affected. The controller can further include instructions that cause the applicator to maintain the lower temperature for a period after the electric field is removed.
Additional embodiments of the disclosure are directed to cosmetic methods for affecting a target region of a human body to achieve a cosmetically beneficial alteration. For example, the method can include removing heat from the target region of the human subject to cool subcutaneous lipid-rich cells in the target region to a temperature below normal body temperature. The method can also include delivering energy to the target region to produce an electric field in an amount sufficient to create pores in membranes of the subcutaneous lipid-rich cells that have been cooled to the temperature below normal body temperature. The pores can compromise cell volume and/or cell viability, and the method can thereby achieve a cosmetically beneficial alteration of subcutaneous adipose tissue.
Some of the embodiments disclosed herein can be for cosmetically beneficial alterations of a variety of body regions. As such, some treatment procedures may be for the sole purpose of altering the body region to conform to a cosmetically desirable look, feel, size, shape or other desirable cosmetic characteristic or feature. Accordingly, at least some embodiments of the cosmetic procedures can be performed without providing any, or in another embodiment, providing minimal therapeutic effect. For example, some treatment procedures may be directed to treatment goals that do not include restoration of health, physical integrity, or the physical well being of a subject. In other embodiments, however, the cosmetically desirable treatments may have therapeutic outcomes (whether intended or not), such as, psychological benefits, alteration of body hormones levels (by the reduction of adipose tissue), etc. The cosmetic methods can target subcutaneous regions to change a subject's appearance such as, for example, procedures performed on a subject's “love-handles” (i.e., excess adipose tissue at the side of a subject's waistline).
In one embodiment, the multi-modality treatment system 100 is suitable for altering a human subject's subcutaneous adipose tissue, including such as by cooling and/or by delivering energy. The term “subcutaneous tissue” means tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue, which primarily is composed of lipid-rich cells, or adipocytes. Such alteration (e.g., by cooling, energy delivery and/or combination of cooling and energy delivery) is believed to be an intermediate and/or final result of one or more mechanisms acting alone or in combination. It is thought that such mechanism or mechanisms can trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling alone or in combination with other forms of cell interrogation.
In several embodiments, apoptosis of the subcutaneous lipid-rich cells in the region of the subject 101 being treated is a desirable outcome for beneficially altering (e.g., sculpting and/or reducing) adipose tissue. Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation, and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990). One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by, for example, macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response.
Without being bound by theory, one mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids may selectively injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bilayer lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bilayer lipid membrane, which results in membrane disruption, thereby inducing apoptosis. This mechanism is well documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Other possible mechanisms of adipocyte damage, described in U.S. Pat. No. 8,192,474, relates to ischemia/reperfusion injury that may occur under certain conditions when such cells are cooled as described herein. For instance, during treatment by cooling as described herein, the targeted adipose tissue may experience a restriction in blood supply and thus be starved of oxygen due to isolation while pulled into, e.g., a vacuum cup, or simply as a result of the cooling which may affect vasoconstriction in the cooled tissue. In addition to the ischemic damage caused by oxygen starvation and the build up of metabolic waste products in the tissue during the period of restricted blood flow, restoration of blood flow after cooling treatment may additionally produce reperfusion injury to the adipocytes due to inflammation and oxidative damage that is known to occur when oxygenated blood is restored to tissue that has undergone a period of ischemia. This type of injury may be accelerated by exposing the adipocytes to an energy source (via, e.g., thermal, electrical, chemical, mechanical, acoustic or other means) or otherwise increasing the blood flow rate in connection with or after cooling treatment as described herein. Increasing vasoconstriction in such adipose tissue by, e.g., various mechanical means (e.g., application of pressure or massage), chemical means or certain cooling conditions, as well as the local introduction of oxygen radical-forming compounds to stimulate inflammation and/or leukocyte activity in adipose tissue may also contribute to accelerating injury to such cells. Other yet-to-be understood mechanisms of injury may exist.
In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure may induce lipolysis (i.e., fat metabolism) of lipid-rich cells. For example, cold stress has been shown to enhance rates of lipolysis from that observed under normal conditions which serves to further increase the volumetric reduction of subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).
When cooling the subcutaneous tissues to a temperature lower than 37° C., subcutaneous lipid-rich cells can selectively be affected. In general, the epidermis and dermis of the subject 101 have lower amounts of lipids compared to the underlying lipid-rich cells forming the subcutaneous tissues. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells selectively can be affected while maintaining the integrity of the non-lipid-rich cells in the dermis and/or epidermis. In some embodiments, the multi-modality treatment system 100 can cool the skin of the patient to a temperature in a range of from about −20° C. to about 20° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 10° C., from about −15° C. to about 5° C., or from about −10° C. to about 0° C.
Without being bound by theory, the selective effect of cooling on lipid-rich cells is believed to result in, for example, membrane disruption, shrinkage, disabling, destroying, removing, killing, or another method of lipid-rich cell alteration. Depending on the duration and final cooling temperature, subcutaneous lipid-rich cells can selectively become altered in a manner that makes the cells more susceptible to further interrogation and/or cell injury than non-lipid-rich cells in the same region. Such alteration (e.g., by cooling, energy delivery and/or combination of cooling and energy delivery) is believed to be an intermediate and/or final result of one or more mechanisms acting alone or in combination. It is thought that such mechanism or mechanisms can trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling alone or in combination with other forms of cell interrogation. Temperature exposures and/or other energy delivery modalities that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.
One form of cell interrogation is electroporation, or electropermeabilization, which refers to the permeabilization of a cell membrane as a consequence of the application of electric fields. The electric fields can be pulsed or continuous. Short and intense electric fields across the cell membrane, the cells or the tissues can cause permeabilization. The permeabilization can be temporary (e.g., reversible permeabilization) or permanent (e.g., irreversible permeabilization) based on the electric field magnitude, electric field duration, number of pulses, frequency of pulse, duration of pulses, or the like.
Delivery of energy, such as high voltage or low voltage energy, to subcutaneous tissue to generate an electric field across the tissue selectively can increase the electrical conductivity and permeability of the cell plasma membranes of the lipid-rich cells. For a given pulse duration and shape, a specific transmembrane voltage or energy threshold exists for the manifestation of the electroporation phenomenon (e.g., from about 0.5 V to about 1 V, from about 1 V to about 2 V, or from about 2 V to about 5 V per cell). Accordingly, there is an electric field magnitude threshold for electroporation wherein only the cells exposed to an electric field equal to or greater than a first, lower electroporation threshold of the specific cell, can be electroporated (e.g., pores form and/or open in the cell membrane). Above the first, lower electroporation threshold, the number of pores and/or the pore diameter increases with both the amplitude and duration of the electric field pulses. Removing the electric field pulses enables the induced pores to reseal. Depending on the number, diameter and life time of pores in the membrane, electroporation of the cell may result in significant injury to the cell that can trigger an apoptotic cascade event and eventual cell death. Cells also have a second, upper electroporation threshold which, if exceeded, will compromise the viability of the cells (e.g., the membrane pores will irreversibly be open). If cells become permanently permeable from the formation of pores in the cell membrane, the cells are unable to repair the damage and die due to a loss of homeostasis.
The first, lower electroporation threshold is different for different cells and depends in part on cell size in that the larger the cell size (e.g., as determined by cell volume), the lower the electroporation threshold. For example, the larger the cell, the smaller the electric field required to induce pore formation. Accordingly, larger cells such as lipid-rich cells can selectively be electroporated (reversibly or irreversibly) with external application of electric fields that are lower in magnitude when compared to the magnitude of electric fields required to also electroporate smaller cells (e.g., non-lipid-rich cells).
As described in more detail herein, selective cooling of subcutaneous lipid-rich cells can alter the lipid-rich cells such that these cells are more susceptible to cell injury and interrogation. For example, cooling of subcutaneous lipid-rich cells (e.g., to a temperature below normal body temperature) can lower a transmembrane voltage or energy threshold for the subcutaneous lipid-rich cells such that less energy is required to induce pore formation than would be necessary if the lipid-rich cells were not cooled. In specific examples, the energy required to induce pore formation in cooled subcutaneous lipid-rich cells can be approximately 5% to approximately 50% lower, or in another embodiment approximately 10% to approximately 30% lower, than the energy required to induce pore formation in the non-cooled lipid-rich cells. In other embodiments, the energy required to induce pore formation in cooled subcutaneous lipid-rich cells can be approximately 10%, 15%, 20%, 25% or 30% lower the energy required to induce pore formation in the non-cooled lipid-rich cells. In a further embodiment, cooling subcutaneous lipid-rich cells can lower a transmembrane voltage threshold of the subcutaneous lipid-rich cells by an amount approximately greater than 10%, approximately greater than 20%, or approximately greater than 30%. Accordingly, electrical energy can be subsequently and/or concurrently applied to the target tissue to generate a pulsed electric field that can further selectively disrupt subcutaneous lipid-rich cells and can be delivered at a magnitude that is lower than would otherwise be necessary to induce lipid-rich cell damage and/or death by electroporation. For example, the magnitude of electric field and duration of application sufficient to alter cooled subcutaneous lipid-rich cells can be at a clinically acceptable voltage range (e.g., between approximately 50 V to about 900 V) for noninvasive and cosmetically beneficial treatment and/or reduction in subcutaneous adipose tissue.
In some aspects of the present technology, the subcutaneous tissue can be cooled to a temperature lower than 37° C., which disproportionately affects the lipid-rich cells in the tissue—either injuring them or making them more susceptible to further injury and interrogation. Cooling can be maintained during subsequent application of a pulsed electric field in an amount sufficient to create (e.g., form, open, etc.) pores in membranes of the subcutaneous lipid-rich cells. In further embodiments, cooling can be continued after the pulsed electric field is discontinued or removed to maintain membrane pore stability post-electroporation to promote further cell lysis and/or injury. In other embodiments, cooling and energy delivery can be applied in different protocols. For example, cooling can precede delivery of the pulsed electric field, but be discontinued before or during the electroporation portion of the treatment.
As described above, cooling the subcutaneous tissues to a temperature lower than 37° C. selectively can affect lipid-rich cells. Cooling the lipid-rich cells of the subcutaneous layer tends uniformly to affect the adipose cells distributed throughout the subcutaneous tissue at a given depth below the dermis, for instance, when such lipid-rich cells are cooled non-invasively. Accordingly, in one embodiment, the multi-modality treatment system 100 (
As shown in
In another embodiment shown in
Other methods of applying energy selectively to alter subcutaneous tissue as described herein may be used in addition to or in place of cooling combined with electroporation, including, e.g., radiofrequency (RF) energy, optical (e.g., laser light), acoustic (e.g., ultrasound, high-frequency ultrasound), infrared, microwave, etc.
In the treatment therapy associated with the embodiments described herein, the treatment parameters may be adjusted to affect, in connection with cooling the subcutaneous tissue, the temperature profile of and the number of the adipose cells in the subcutaneous tissue within the target region that are electroporated via the application of such an electric field or interrogated by another external energy modality. For example, applied energy in the range of about 50 V to about 1000 V or lower after or during cooling can have the desired effect of selectively altering or reducing subcutaneous adipose tissue in the target region.
In some embodiments, the multi-modality treatment system 100 can be configured to apply cooling treatment before and/or during application of energy to the skin of the subject 101 to generate an electric field in a simultaneous manner, or in a sequential manner, such that the subcutaneous lipid-rich cells are cooled to a temperature less than 37° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 20° C., from about −20° C. to about 10° C., from about −15° C. to about 5° C., or from about −10° C. to about 0° C.
In additional embodiments, the multi-modality treatment system 100 can be configured to apply cooling treatment and/or to maintain cooling treatment after the subcutaneous lipid-rich cells have been electroporated. For example, heat can be removed from the target region to reduce a natural body temperature to a lower temperature in the target region, and then the lower temperature can be maintained for a period (e.g., time) after the electric field is removed. In one embodiment the period can be between about 1 minute and about 2 hours, between about 1 minute and about 1 hour, between about 1 minute and about 50 minutes, between about 1 minute and about 40 minutes, between about 1 minute and about 30 minutes, or between about 1 minute and about 20 minutes. Other periods of time can be used. Still another embodiment results in maintaining the lower temperature for between about 5 minutes and about 15 minutes post-electroporation. In other embodiments, the electric field can be applied to the target region of the subject 101 simultaneously with cooling (i.e., removing heat), before, periodically during, or after cooling for selectively affecting the lipid-rich cells in the subcutaneous layer of the subject 101.
In various embodiments, the multi-modality treatment system 100 includes a controller, a computing device, a data acquisition device, a chiller, and one or more multi-modality applicators. These components can be implemented in various embodiments to apply selected treatment profiles to a subject 101 (e.g., a human or an animal) for reducing or altering adipose tissue.
Referring again to
An applicator 104 is a component of the system 100 that both cools subcutaneous tissue and selectively applies energy to (e.g., electroporates) lipid-rich cells in a subcutaneous region of a subject 101 (i.e., “patient”). Various types of applicators may be applied during treatment, such as a vacuum applicator, a belt applicator (either of which may be used in combination with a massage or vibrating capability), and so forth. Each applicator 104 may be designed to treat identified portions of the patient's body, such as chin, cheeks, arms, pectoral areas, thighs, calves, buttocks, abdomen, “love handles”, back, and so forth. For example, the vacuum applicator may be applied at the back region, and the belt applicator can be applied around the thigh region, either with or without massage or vibration. Exemplary applicators and their configurations usable or adaptable for use with the multi-modality treatment system 100 variously are described in, e.g., commonly assigned U.S. Pat. No. 7,854,754 and U.S. Patent Publication Nos. 2008/0077201, 2008/0077211 and 2008/0287839. In further embodiments, the system 100 may also include a patient protection device (not shown) incorporated into or configured for use with the applicator 104 that prevents the applicator from directly contacting a patient's skin and thereby reducing the likelihood of cross-contamination between patients, minimizing cleaning requirements for the applicator. The patient protection device may also include or incorporate various storage, computing, and communications devices, such as a radio frequency identification (RFID) component, allowing for example, use to be monitored and/or metered. Exemplary patient protection devices are described in commonly assigned U.S. Patent Publication No. 2008/0077201.
In the present example, the system 100 can also include a treatment unit 106 and supply and return fluid lines 108a-b between the multi-modality applicator 104 and the treatment unit 106. A treatment unit 106 is a device that can increase or decrease the temperature at a connected multi-modality applicator 104 that is configured to engage the subject and/or the target region of the subject. The treatment unit 106 can remove heat from a circulating coolant to a heat sink and provide a chilled coolant to the multi-modality applicator 104 via the fluid lines 108a-b. Alternatively, the treatment unit 106 can circulate warm coolant to the multi-modality applicator 104 during periods of warming. In further embodiments, the treatment unit 106 can circulate coolant through the multi-modality applicator 104 and increase or decrease the temperature of the multi-modality applicator by controlling power delivery to one or more Peltier-type thermoelectric elements incorporated within the multi-modality applicator. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and/or any other suitable heat conducting fluid. The fluid lines 108a-b can be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane, and/or other materials that can accommodate the particular circulating coolant. The treatment unit 106 can be a refrigeration unit, a cooling tower, a thermoelectric chiller, or any other device capable of removing heat from a coolant. In one embodiment, the treatment unit 106 can include a fluid chamber 105 configured to house and provide the coolant. Alternatively, a municipal water supply (e.g., tap water) can be used in place of or in conjunction with the treatment unit 106. In a further embodiment, the multi-modality applicator 104 can be a fluid-cooled applicator capable of achieving a desired temperature profile such as those described in U.S. patent application Ser. No. 13/830,027 (U.S. Pub. No. 2014/0277302), filed Mar. 14, 2013, and incorporated herein by reference in its entirety. One skilled in the art will recognize that there are a number of other cooling technologies that could be used such that the treatment unit, chiller, and/or applicator need not be limited to those described herein.
The system 100 can further include an energy generating unit 107, such as an electroporation pulse generator, and power lines 109a-b between the applicator 104 and the energy generating unit 107. In other embodiments (e.g., having a monopolar configuration), the system 100 can include a current return electrode 111 located separately from the applicator 104; power line 109c (shown in dotted line) can electrically connect the return electrode 111, if present, and the energy generating unit 107. The energy generating unit 107 can include an electroporation pulse generator, such as a high voltage or low voltage pulse generator, capable of generating and delivering a high or low voltage current, respectively, through the power lines 109a, 109b to one or more electrodes (e.g., cathode, anode) in the multi-modality applicator 104 for generating and delivering a pulsed electric field to the target region of the subject 101, wherein the pulsed electric field strength exceeds a transmembrane potential of a subcutaneous lipid-rich cell. In other embodiments, the energy generating unit 107 can include a variable powered RF generator capable of generating and delivering RF energy, such as RF pulses, through the power lines 109a, 109b or to other power lines (not shown). In a further embodiment, the energy generating unit 107 can include a microwave pulse generator, an ultrasound pulse laser generator, or high frequency ultrasound (HIFU) phased signal generator, or other energy generator suitable for applying energy, for example, to further interrogate cooled lipid-rich cells in subcutaneous layers. In additional embodiments, the system 100 can include more than one energy generator unit 107 such as any one of a combination of the energy modality generating units described herein.
A dielectric element (e.g., layer or film) may be used on the one or more electrodes to increase the impedance of the electrode and produce a more uniform current flow through the electrode(s) to the skin of the subject 101. Such an element creates a capacitance effect whose magnitude and other qualities may be controlled by the composition, surface area and thickness of the layer, the choice of methods by which the layer or film is deposited and/or adhered to the electrode, and/or the frequency of the signal. Alternatively, the system 100 can be configured to use an electrode without a dielectric element. The choice of whether to use a dielectric element may be predicated upon the particular design of the electrode, the location on the patient which the system 100 is used, frequency and power settings, temperatures, treatment duration, and other such parameters and other considerations.
In the illustrated example, the multi-modality applicator 104 is associated with at least one treatment unit 106. The applicator 104 can provide mechanical energy to create a vibratory, massage, and/or pulsatile effect. The applicator 104 can include one or more actuators, such as, motors with eccentric weight, or other vibratory motors such as hydraulic motors, electric motors, pneumatic motors, solenoids, other mechanical motors, piezoelectric shakers, and so on, to provide vibratory energy or other mechanical energy to the treatment site. Further examples include a plurality of actuators for use in connection with a single multi-modality applicator 104 in any desired combination. For example, an eccentric weight actuator can be associated with one section of a multi-modality applicator 104, while a pneumatic motor can be associated with another section of the same applicator 104. This, for example, would give the operator of the multi-modality treatment system 100 options for differential treatment of lipid-rich cells within a single region or among multiple regions of the subject 101. The use of one or more actuators and actuator types in various combinations and configurations with a multi-modality applicator 104 may be possible.
The multi-modality applicator 104 can include one or more heat exchanging units. Each heat exchanging unit can include or be associated with one or more Peltier-type thermoelectric elements, and the multi-modality applicator 104 can have multiple individually controlled heat exchanging zones (e.g., between 1 and 50, between 10 and 45; between 15 and 21, approximately 100, etc.) to create a custom spatial cooling profile and/or a time-varying cooling profile. Each custom treatment profile can include one or more segments, and each segment can include a specified duration, a target temperature, and control parameters for features such as vibration, massage, vacuum, and other treatment modes. Applicators having multiple individually controlled heat exchanging units are described in commonly assigned U.S. Patent Publication Nos. 2008/0077211 and 2011/0238051.
Additionally, the multi-modality applicator 104 can include one or more electrodes, such as flat plate electrodes for delivering electrical pulse or pulses to the target region. For example, the electrodes can be a single electrode or a plurality of electrodes positioned in a desired or segmented arrangement and, in some embodiments, can form a segmented flexible circuit. Electrical pulses can be delivered to the electrodes at a predetermined voltage, frequency and duration via the power lines 109a, 109b and, thereafter, coupled to the target region of the subject 101 to generate an electric field sufficient to create and, in some embodiments, maintain open pores in membranes of the subcutaneous lipid-rich cells. Generally, electrodes can be arranged in monopolar or bipolar configurations. When using bipolar electrodes, the current passes through the tissue of the target region and between two electrodes located a predetermined distance apart. While the propagation of the current is limited to the region generally between the electrodes themselves, bipolar electrode configurations can provide a suitable distribution of energy and generate pore formation and growth on multiple sides of cell membranes. While not being bound by theory, useful ranges of applied voltage, frequency and pulse duration in such a bipolar electrode configuration can, in some embodiments and with use of some applicators, devices and systems, be between about 5 V/cm to 200 V/cm, 10 kHz to 100 kHz, and 1 millisecond (msec) to 100 msec, respectively. In other embodiments, useful ranges of applied voltage, frequency and pulse duration for a bipolar electrode configuration can be between about 200 V/cm to 1,500 V/cm, 50 kHz to 1 MHz, and 10 microseconds (μsec) to 1 msec, respectively. In further embodiments, useful ranges of applied voltage, frequency and pulse duration can be about 10 V/cm to 1 kV/cm, 50 kHz to 5 MHz, and 1 msec to 10 seconds, respectively. Other ranges of applied voltage, frequency, pulse duration as well as other electric pulse characteristics including waveform shape (square, triangular, circular, exponential, etc.) and time delay in a pulse sequence, are possible, such as those described in U.S. Pat. No. 7,054,685.
Monopolar electrode configurations are configured to have current flow from an electrode within the multi-modality applicator 104 into the epidermis and dermis, through the subcutaneous tissue until it reaches a location wherein it has dissipated to a level that it does not have any appreciable effect. The current generated by a monopolar electrode can generate an electric field sufficient to form pores in membranes of the subcutaneous lipid-rich cells (e.g., on at least one side of the cell membrane) where it then continues to flow through the body to the return electrode 111. The return electrode 111 can be adhered to a second site on the subject 101 and the current can return to the energy generating unit 107 via the power line 109c. Alternatively, the multi-modality applicator 104 may operate without a return electrode and power return line. At sufficiently high RF frequencies (e.g., greater than about 1 MHz), the return current can flow out of the body and through the air to the energy generating unit 107 to complete the circuit. While not being bound by theory, useful ranges of applied voltage, frequency and pulse duration in such a configuration, sometimes referred to a “unipolar” configuration, can be between about 1 kV to 30 kV, 1 MHz to 60 MHz, and 100 μsec to 100 msec, respectively. In other embodiments and with use of some applicators, devices and systems, useful ranges of applied voltage, frequency and pulse duration for a monopolar electrode configuration can be between about 100 V to 1 kV, 20 kHz to 200 kHz, and 10 μsec to 1 msec, respectively. In further embodiments, useful ranges of applied voltage, frequency and pulse duration can be about 50 V to 500 V, 50 kHz to 10 MHz, and 1 msec to 10 seconds, respectively.
The system 100 can further include a power supply 110 and a controller 114 operatively coupled to the multi-modality applicator 104. In one embodiment, the power supply 110 can provide a direct current voltage to the applicator 104 to remove heat from the subject 101. The controller 114 can monitor process parameters via sensors (not shown) placed proximate to the multi-modality applicator 104 via a control line 116 to, among other things, adjust the heat removal rate and/or energy delivery rate based on the process parameters. The controller 114 can further monitor process parameters to adjust the applicator 104 based on treatment parameters, such as treatment parameters defined in a custom treatment profile or patient-specific treatment plan, such as those described, for example, in commonly assigned U.S. Pat. No. 8,275,442.
The controller 114 can exchange data with the applicator 104 via an electrical line 112 or, alternatively, via a wireless or an optical communication link. Note that control line 116 and electrical line 112 are shown in
The controller 114 can include any processor, Programmable Logic Controller, Distributed Control System, secure processor, and the like. A secure processor can be implemented as an integrated circuit with access-controlled physical interfaces; tamper resistant containment; means of detecting and responding to physical tampering; secure storage; and shielded execution of computer-executable instructions. Some secure processors also provide cryptographic accelerator circuitry. Secure storage may also be implemented as a secure flash memory, secure serial EEPROM, secure field programmable gate array, or secure application-specific integrated circuit.
In another aspect, the controller 114 can receive data from an input device 118 (shown as a touch screen), transmit data to an output device 120, and/or exchange data with a control panel (not shown). The input device 118 can include a keyboard, a mouse, a stylus, a touch screen, a push button, a switch, a potentiometer, a scanner, an audio component such as a microphone, or any other device suitable for accepting user input. The output device 120 can include a display or touch screen, a printer, video monitor, a medium reader, an audio device such as a speaker, any combination thereof, and any other device or devices suitable for providing user feedback.
In the embodiment of
In operation, and upon receiving input to start a treatment protocol, the controller 114 can cause one or more power supplies 110, one or more treatment units 106, and one or more multi-modality applicators 104 to cycle through each segment of a prescribed treatment plan. In so doing, power supply 110 and treatment unit 106 provide coolant and power to one or more functional components of the applicator 104, such as thermoelectric coolers (e.g., TEC “zones”), to begin a cooling cycle and, for example, activate features or modes such as vibration, massage, vacuum, etc. Additionally, the energy generating unit 107 is used to generate and transfer electrical pulse or pulses to the electrodes in the one or more functional components of the applicator 104 to begin selectively electroporating cooled lipid-rich cells in the subcutaneous tissue in the target region of the subject 101.
Using temperature sensors (not shown) proximate to the one or more multi-modality applicators 104, the patient's skin, a patient protection device, or other locations or combinations thereof, the controller 114 can determine whether a temperature or heat flux is sufficiently close to the target temperature or heat flux. It will be appreciated that while a region of the body (e.g., adipose tissue) has been cooled or heated to the target temperature, in actuality that region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the system may attempt to heat or cool the tissue to the target temperature or to provide a target heat flux, a sensor may measure a sufficiently close temperature or heat flux. If the target temperature has not been reached, power can be increased or decreased to change heat flux to maintain the target temperature or “set-point” selectively to affect lipid-rich subcutaneous adipose tissue.
When the prescribed segment duration expires, the controller 114 may apply the temperature and duration indicated in the next treatment profile segment. In some embodiments, temperature can be controlled using a variable other than or in addition to power.
In some embodiments, heat flux measurements can indicate other changes or anomalies that can occur during treatment administration. For example, an increase in temperature detected by a heat flux sensor can indicate a freezing event at the skin or underlying tissue (i.e., dermal tissue). An increase in temperature as detected by the heat flux sensors can also indicate movement associated with the applicator, causing the applicator to contact a warmer area of the skin, for example. Methods and systems for collection of feedback data and monitoring of temperature measurements are described in commonly assigned U.S. Pat. No. 8,285,390.
The multi-modality applicators 104 may also include additional sensors to detect process treatment feedback. For example, thermal sensors can be included on the multi-modality applicator 104 and/or the energy generating unit 107 to measure voltage and current that is delivered to the target region of the subject 101. Thermal sensor output can be used, by the controller 114 for example, to control the delivery of power to the electrodes, the temperature of the electrodes or the desired electrical field strength and location during a treatment session. Additional sensors may be included for measuring tissue impedance, treatment application force, tissue contact with the applicator and energy interaction with the skin of the subject 101 among other process parameters.
In one embodiment, feedback data associated with energy delivery and heat removal from lipid-rich cells in the subcutaneous layer can be collected in real-time. Real-time collection and processing of such feedback data can be used in concert with treatment administration to ensure that the process parameters used to alter or reduce subcutaneous adipose tissue are administered correctly and efficaciously.
According to examples of the system 100, the multi-modality applicator 104 enhances disruption of cooled adipose tissue through further cell interrogation, such as via electroporation. Further, the examples can provide reduced treatment time, reduced discomfort to the patient, and increased efficacy of treatment.
Examples of the system 100 may provide the multi-modality applicator 104 which damages, injures, disrupts or otherwise reduces subcutaneous lipid-rich cells generally without collateral damage to non-lipid-rich cells in the treatment region. In general, it is believed that lipid-rich cells selectively can be affected (e.g., damaged, injured, or disrupted) by exposing such cells to low temperatures that do not so affect non-lipid-rich cells. Moreover, as discussed above, electrical pulses can be administered simultaneously and/or in consecutive fashion to further selectively interrogate lipid-rich cells in the treatment region so as to beneficially and cosmetically alter subcutaneous adipose tissue. As a result, lipid-rich cells, such as subcutaneous adipose tissue, can be damaged while other cells in the same region are generally not damaged even though the non-lipid-rich cells at the surface may be subject to even lower temperatures. The mechanical energy provided by the applicator 104 may further enhance the effect on lipid-rich cells by mechanically disrupting the affected lipid-rich cells.
In some examples of the system 100, a cryoprotectant is used with the applicator 104 to, among other advantages, assist in preventing freezing of non lipid-rich tissue (e.g., dermal tissue) during treatment as is described in commonly-assigned U.S. Patent Publication No. 2007/0255362.
In one mode of operation, the applicator 104 may be configured to be a handheld device such as the device disclosed in commonly-assigned U.S. Pat. No. 7,854,754.
Applying the multi-modality applicator 104 with pressure or with a vacuum type force to the subject's skin or pressing against the skin can be advantageous to achieve efficient treatment. In general, the subject 101 has a body temperature of about 37° C., and the blood circulation is one mechanism for maintaining a constant body temperature. As a result, blood flow through the skin and subcutaneous layer of the region to be treated can be viewed as a heat source that counteracts the cooling of the subdermal fat. As such, cooling the tissue of interest requires not only removing the heat from such tissue but also that of the blood circulating through this tissue. Thus, temporarily reducing or eliminating blood flow through the treatment region, by means such as, e.g., applying the applicator with pressure, can improve the efficiency of tissue cooling and avoid excessive heat loss through the dermis and epidermis. Additionally, a vacuum can pull skin away from the body which can assist in cooling targeted underlying tissue.
By cooling the subcutaneous tissue to a temperature lower than 37° C., prior to or during electroporation of subcutaneous lipid-rich cells, these cells can selectively be damaged with clinically acceptable voltage pulses in voltage ranges lower than that required for electroporation without cooling. In general, the cells forming the epidermis and dermis of the subject 101 have lower amounts of lipids and are smaller in size compared to the underlying lipid-rich cells forming the subcutaneous tissues. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells and have higher transmembrane potentials, the subcutaneous lipid-rich cells can selectively be injured while maintaining the non-lipid-rich cells in the dermis and epidermis.
Bipolar electrical pulses, such as high voltage or low voltage electrical pulses, generated by the energy generating unit 107 (
The energy exchanging plates 410a, 410b can contain one or more communication components 415 (shown individually as 415a and 415b) that communicate with the controller 114 to provide a first sensor reading 442 as described herein, and one or more sensors 417 (shown individually as 417a and 417b) that measure, e.g., temperature of the energy exchanging plates 410a, 410b, heat flux across a surface of or plane within the energy exchanging plates 410a, 410b or voltage readings. The interface layer 420 can be a plate, a film, a covering, a sleeve or other suitable materials described herein and may serve as the patient protection device described herein. The interface layer 420 is located between the energy exchanging plates 410a, 410b and the skin 430 of a subject (not shown), such as the skin of a patient receiving treatment via the multi-modality applicator 400. Other interface layers may be present.
The interface layer 420 can also contain one or more similar communication components 425 (shown individually as 425a and 425b) that communicate with the controller 114 to provide a second sensor reading 444 and one or more sensors 427 (individually shown as 427a and 427b) that measure, e.g., the temperature of different portions of the interface layer 420, heat flux across a surface of or plane within the interface layer 420, voltage readings or contact pressure with the skin 430 of the patient. For example, one or both of the communication components 415, 425 can receive and transmit information from the controller 114, such as temperature and/or heat flux information as determined by one or both of the sensors 417, 427. The sensors 417, 427 can be configured to measure a parameter of the interface without substantially impeding heat transfer between the energy exchanging plates 410a, 410b and the subject's skin 430. The applicator 400 can also contain power components and other components described with respect to
In certain embodiments, the multi-modality applicator 400 can include a dielectric sleeve 450 for contacting the patient's skin 430 and for achieving a more uniform distribution of electrical pulses, such as bipolar rectangular pulses, into the patient's underlying subcutaneous tissue. The sleeve 450 can include a first sleeve portion 452 and a second sleeve portion 454 extending from the first sleeve portion. The first sleeve portion 452 can contact and/or facilitate the contact of the multi-modality applicator 400 with the patient's skin 430, while the second sleeve portion 454 can be an isolation layer extending from the first sleeve portion 452. The second sleeve portion 454 can be constructed from latex, rubber, nylon, Kevlar®, or other substantially impermeable or semi-permeable material. The second sleeve portion 454 can prevent contact between the patient's skin 430 and the energy exchanging plates 410a, 410b, among other things.
The surface of the first sleeve portion 452 can include a dielectric or variable resistance material providing an insulator between the electrically conductive energy exchanging plates 410a, 410b and the interface layer 420 and the patient's skin 430. For example, the material can include material coated or comprised of Teflon®, silicon nitride, polysilanes, polysilazanes, polyimides (such as, e.g., Kapton® film) and other polymers or dielectric materials well known in the art. The capacitive effect of the dielectric layer (e.g., the first sleeve portion 452) can be controlled, for example, through sleeve thickness, surface area, the dielectric constant of the material and the electrical pulses generated. In some embodiments, the first sleeve portion 452 extends beyond the edges of the electrically conductive energy exchanging plates 410a, 410b and/or other electrodes such that the electrical pulses are required to flow through the dielectric material of the first sleeve portion 452. Further details regarding a suitable sleeve may be found in U.S. Patent Publication No. 2008/0077201.
In other embodiments, the multi-modality applicator 400 can include a belt that assists in forming a contact between the applicator 400 (such as via an interface layer 420) and the patient's skin 430. For example, the applicator 400 can include retention devices (not shown) coupled to a frame. The retention devices may be rotatably connected to the frame by a plurality of coupling elements that can be, for example, pins, ball joints, bearings, or other type of rotatable joints. Alternatively, the retention devices can be rigidly affixed to the end portions of heat exchanging element housings. Further details regarding a suitable belt device may be found in U.S. Patent Publication No. 2008/0077211.
In further embodiments, the multi-modality applicator 400 can include a vacuum (not shown) that assists in forming a contact between the applicator 400 (such as via the interface layer 420 or dielectric sleeve 450) and the patient's skin 430. For example, the applicator 400 can provide mechanical energy to a treatment region. Imparting mechanical vibratory energy to the patient's tissue by repeatedly applying and releasing a vacuum to the subject's tissue, for instance, creates a massage action during treatment. Further details regarding a vacuum type device may be found in U.S. Patent Application Publication No. 2008/0287839.
The interface layers 514a and 514b are adjacent to the flat plate electrodes 512a and 512b, respectively. Similar to the interface layer 420 illustrated in
In operation, the rim 516 of the vacuum cup 502 is placed against the skin of a subject (not shown) and a vacuum is drawn within the cup 502. The vacuum pulls the tissue of the subject into the cup 502 and coapts the target area with the interface layers 514a and 514b of the corresponding first and second applicator units 510a, 510b. One suitable vacuum cup 502 with cooling units is described in U.S. Pat. No. 7,367,341.
The applicator units 510a and 510b can be in communication with the controller 114, treatment unit 106, energy generating unit 107 and power supply 110 (
The electrodes 512a, 512b can also, either concurrently to cooling or sequential to the cooling step, deliver electrical pulses, such as bipolar pulses in the range of about 50 V to about 900 V with a duration of about 10 microseconds to about 1 milliseconds. In some embodiments, cooling can be continued or re-administered to the target region following the energy application to further interrogate the lipid-rich cells, such as to prevent pores in the cell membrane (e.g., caused by electroporation) from closing. The energy generating unit 107 and/or power supply 110 (
Although a noninvasive applicator unit is illustrated and discussed with respect to
The electrode arrays 614a, 614b can include one or more retractable tissue piercing electrodes 616. The retractable tissue piercing electrodes 616 can, in one embodiment, be electrode needles that move inwardly (indicated by arrows 618 and 620) after the tissue is pre-cooled and numb by the cooling and/or by other means (topical agents such as lidocane, injectable agents, etc.). Once inserted into the tissue of the target region at a desirable depth, the tissue piercing electrodes 616 can deliver a desired voltage pulse(s) across the tissue to achieve selective electroporation of subcutaneous lipid-rich cells. Once electroporation has occurred, the tissue piercing electrodes 616 can be withdrawn and retracted into the applicator units 610a, 610b while the cooling plates 612 can continue to maintain the target region tissue at a cold temperature (e.g., below 37° C.). The applicator 600 can include one or more actuators, drive devices, or other components that move the retractable tissue piercing electrodes 616. The first and second applicator units 610a, 610b may also, optionally, include an interface layer (not shown), a dielectric layer (not shown) or both.
In further embodiments, the system 100 and any one of the multi-modality applicators 104, 400, 500 and 600 can be configured to cool tissue to enhance lysis of lipid-rich cells caused by RF pulses, micropulses, ultrasound pulses, or other types of delivered energy. For example, as has been disclosed herein with respect to the present technology, pore formation, pore growth, and cell membrane permeability, such as that for large lipid-rich cells in subcutaneous adipose tissue, are dependent and/or correlate with the temperature of the target cells prior to, during, and after the electrical pulse interrogation of the cells. In one embodiment, the objective of subcutaneous adipose tissue alteration and reduction therapy can be achieved by keeping cell pores open for periods of time (e.g., minutes) longer than electrical energy administration to allow for greater cell lysis and cell death. Accordingly, embodiments described herein can achieve this objective by in vivo cooling of the subcutaneous lipid-rich cells pre-, during and post-electrical energy application. In various arrangements, subcutaneous adipose tissue reduction can be enhanced with electroporation when compared to cooling alone. Likewise, voltage applied across a target tissue region to achieve electroporation of subcutaneous lipid-rich cells can be at a lower voltage gradient when applied to cooled cells than when compared to non-cooled cells.
Features of the multi-modality system and device components described above and illustrated in
In other examples, the multi-modality system and devices described herein can be combined with additional modalities to enhance the therapeutic and cosmetic effects on and alterations (e.g., reduction) of subcutaneous adipose tissue and/or enhance preservation or viability of non-lipid-rich cells in the target region. These can include, for example, delivery of drugs, vaccines and gene therapy that can, for example, be introduced into the electroporated cells via the open pores.
Features of the multi-modality system and device components described above also can be interchanged to form additional embodiments of the present technology. For example, the retractable and/or minimally invasive electrodes 616 of the applicator units 610a, 610b illustrated in
The system 100 (
As shown in
The method 700 can also include removing heat from the target region of the subject (e.g., human or animal patient) during a treatment process selectively to cool subcutaneous lipid-rich cells in the target region to a temperature below normal body temperature (block 704). For example, the lipid-rich tissue can be cooled to a temperature below about 37° C., below about 20° C., below about 10° C. or below about 0° C. such that lipid-rich cells are affected without substantially affecting non-lipid-rich cells.
In block 706, the method 700 also includes delivering electrical energy to the target region to produce a pulsed electric field in an amount sufficient to create and/or open pores in membranes of the subcutaneous lipid-rich cells that have been cooled to the temperature below normal body temperature, wherein the pores compromise either cell volume or cell viability. In some embodiments, the electrical energy may be monopolar while in other embodiments it may be bipolar. In some embodiments, the electrical energy includes an applied voltage between two or more electrodes. In one embodiment, the applied voltage can be delivered at a voltage range from about 50 V to about 900 V with a pulse duration of about 10 microseconds to about 1.0 milliseconds. In some embodiments, delivering electrical energy to the target region affects subcutaneous lipid-rich cells without substantially affecting non-lipid-rich cells. In various embodiments, energy application parameters can be predetermined such that the electrical energy delivered to the target region irreversibly creates and/or opens pores in the membranes of the subcutaneous lipid-rich cells, thereby allowing the subcutaneous lipid-rich cells to lyse. In another example, energy application parameters can be predetermined such that the electrical energy delivered to the target region reversibly creates and opens pores in the membranes of the subcutaneous lipid-rich cells, thereby allowing a lipid volume of the subcutaneous lipid-rich cells to be reduced. One of ordinary skill in the art will recognize that the voltage applied across the tissue of the target region can be calculated according to the tissue characteristics and thickness, desired depth of the electric field, the distance between positive (+) and negative (−) electrodes, and/or the pulse duration and frequency among other factors. In some aspects, delivering energy to the target region to produce a pulsed electric field includes selectively electroporating lipid-rich cells that have been cooled to a temperature below approximately 10° C. to about 15° C.
Removing heat from the target region may occur before delivery of the energy to the target region; however in other embodiments, removing heat from the subcutaneous layer in the target region may occur simultaneously to energy delivery. For example, the treatment method 700 may include a single stage or multiple stages of delivering energy with each such stage occurring simultaneously with a single stage or multiple stages of removing heat from the lipid-rich cells in the target region. In some treatment regimes, removing heat from the target region can precede and occur simultaneously to energy delivery to the same region, and optionally, heat removal can continue post-energy delivery.
Alternatively, removing heat from the subcutaneous layer and delivering the energy to the target region may occur sequentially. For example, the method 700 may consist of a single stage of removing heat from the lipid-rich cells in the target region that ceases prior to a single stage of delivering energy to the lipid-rich cells in the target region. Additionally, such sequential application of the aforementioned stages may occur multiple times so that multiple non-overlapping stages of energy delivery and heat removal occur.
Another way that method 700 may be accomplished is by periodically or intermittently delivering energy to the target region of the subject simultaneously with removing heat. For example, method 700 may comprise a single stage of removing heat from the lipid-rich cells in the target region during which stage energy is delivered in multiple stages in a regular, periodic fashion or in a less regular, intermittent fashion.
Alternatively, method 700 may include a single stage of delivering energy to the target region during which stage removing heat from the target region is accomplished in multiple stages in a regular, periodic fashion or in a less regular, intermittent fashion.
The duration of delivering the energy and/or amount of voltage applied to the target region according to the embodiments described herein may vary depending on the location of the target region, the degree of warming required, the power setting, whether the energy is delivered as bipolar or monopolar pulses, the parameters of the stage of removing heat to reduce to selectively affect or compromise lipid-rich cells in the subcutaneous layer, and other parameters.
Such a duration may be calculated and described in terms of a single application of energy or cumulatively as summed over the course of more than one application of energy. For example, a single application of energy as described herein may range in duration from 10 microseconds to one or more milliseconds or more. In contrast, the duration of removing heat from the lipid-rich cells in the target region, such as described for example in U.S. Pat. No. 7,367,341, can have a duration of a period of application between about 1 minute and about 2 hours, between about 1 minute and about 1 hour, between about 1 minute and about 50 minutes, or between about 1 minute and about 40 minutes, or between about 1 minute and about 30 minutes, or between about 1 minute and about 20 minutes. Still another embodiment results in a single application of cooling of between about 5 minutes and about 15 minutes. Applying energy in multiple stages as described herein, whether in periodic or intermittent fashion, for example, may also range cumulatively over those multiple stages in duration from a microsecond, a millisecond or less to several seconds or more.
Various aspects of the method 700 can include a cosmetic treatment method for treating the target region of a human subject's body to achieve a cosmetically beneficial alteration of subcutaneous adipose tissue. Such a method could be administered by a non-medically trained person.
As illustrated in
In operation, the input module 808 accepts an operator input 819 via the one or more input devices described above with respect to
In the illustrated example, the process module 812 can generate control variables based on sensor readings 818 from sensors (e.g., the temperature measurement components 417 and 427 of
In various embodiments, the processor 801 can be a standard central processing unit or a secure processor. Secure processors can be special-purpose processors (e.g., reduced instruction set processor) that can withstand sophisticated attacks that attempt to extract data or programming logic. The secure processors may not have debugging pins that enable an external debugger to monitor the secure processor's execution or registers. In other embodiments, the system may employ a secure field programmable gate array, a smartcard, or other secure devices.
The memory 802 can be standard memory, secure memory, or a combination of both memory types. By employing a secure processor and/or secure memory, the system can ensure that data and instructions are both highly secure and sensitive operations such as decryption are shielded from observation.
Suitable computing environments and other computing devices and user interfaces are described in commonly assigned U.S. Pat. No. 8,275,442, entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS,” which is incorporated herein in its entirety by reference.
Various embodiments of the technology are described above. It will be appreciated that details set forth above are provided to describe the embodiments in a manner sufficient to enable a person skilled in the relevant art to make and use the disclosed embodiments. Several of the details and advantages, however, may not be necessary to practice some embodiments. Additionally, some well-known structures or functions may not be shown or described in detail, so as to avoid unnecessarily obscuring the relevant description of the various embodiments. Although some embodiments may be within the scope of the claims, they may not be described in detail with respect to the Figures. Furthermore, features, structures, or characteristics of various embodiments may be combined in any suitable manner. Moreover, one skilled in the art will recognize that there are a number of other technologies that could be used to perform functions similar to those described above and so the claims should not be limited to the devices or routines described herein. While processes or blocks are presented in a given order, alternative embodiments may perform routines having stages, or employ systems having blocks, in a different order, and some processes or blocks may be deleted, moved, added, subdivided, combined, and/or modified. Each of these processes or blocks may be implemented in a variety of different ways. Also, while processes or blocks are at times shown as being performed in series, these processes or blocks may instead be performed in parallel, or may be performed at different times. The headings provided herein are for convenience only and do not interpret the scope or meaning of the claims.
The terminology used in the description is intended to be interpreted in its broadest reasonable manner, even though it is being used in conjunction with a detailed description of identified embodiments.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in a sense of “including, but not limited to.” Words using the singular or plural number also include the plural or singular number, respectively. When the claims use the word “or” in reference to a list of two or more items, that word covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list.
Some of the functional units described herein have been labeled as modules, in order to more particularly emphasize their implementation independence. For example, modules (e.g., modules discussed in connection with
A module may also be implemented as a hardware circuit comprising custom VLSI circuits or gate arrays, off-the-shelf semiconductors such as logic chips, transistors, or other discrete components. A module may also be implemented in programmable hardware devices such as field programmable gate arrays, programmable array logic, programmable logic devices or the like.
A module of executable code may be a single instruction, or many instructions, and may even be distributed over several different code segments, among different programs, and across several memory devices. Similarly, operational data may be identified and illustrated herein within modules, and may be embodied in any suitable form and organized within any suitable type of data structure. The operational data may be collected as a single data set, or may be distributed over different locations including over different storage devices, and may exist, at least partially, merely as electronic signals on a system or network.
Any patents, applications and other references, including any that may be listed in accompanying filing papers, are incorporated herein by reference. Aspects of the described technology can be modified, if necessary, to employ the systems, functions, and concepts of the various references described above to provide yet further embodiments.
These and other changes can be made in light of the above Detailed Description. While the above description details certain embodiments and describes the best mode contemplated, no matter how detailed, various changes can be made. Implementation details may vary considerably, while still being encompassed by the technology disclosed herein. As noted above, particular terminology used when describing certain features or aspects of the technology should not be taken to imply that the terminology is being redefined herein to be restricted to any specific characteristics, features, or aspects of the technology with which that terminology is associated. In general, the terms used in the following claims should not be construed to limit the claims to the specific embodiments disclosed in the specification, unless the above Detailed Description section explicitly defines such terms. Accordingly, the actual scope of the claims encompasses not only the disclosed embodiments, but also all equivalents.
| Number | Name | Date | Kind |
|---|---|---|---|
| 681806 | Mignault et al. | Sep 1901 | A |
| 889810 | Robinson et al. | Jun 1908 | A |
| 2516491 | Swastek | Jul 1950 | A |
| 2726658 | Chessey | Dec 1955 | A |
| 2766619 | Tribus et al. | Oct 1956 | A |
| 2851602 | Cramwinckel et al. | Sep 1958 | A |
| 3093135 | Hirschhorn | Jun 1963 | A |
| 3132688 | Nowak | May 1964 | A |
| 3282267 | Eidus | Nov 1966 | A |
| 3502080 | Hirschhorn | Mar 1970 | A |
| 3587577 | Zubkov et al. | Jun 1971 | A |
| 3591645 | Selwitz | Jul 1971 | A |
| 3703897 | Mack et al. | Nov 1972 | A |
| 3710784 | Taylor | Jan 1973 | A |
| 3786814 | Armao | Jan 1974 | A |
| 3827436 | Andera et al. | Aug 1974 | A |
| 3942519 | Shock | Mar 1976 | A |
| 3948269 | Zimmer | Apr 1976 | A |
| 3986385 | Johnston et al. | Oct 1976 | A |
| 3993053 | Grossan | Nov 1976 | A |
| 4002221 | Buchalter | Jan 1977 | A |
| 4026299 | Sauder | May 1977 | A |
| 4140130 | Storm | Feb 1979 | A |
| 4149529 | Copeland et al. | Apr 1979 | A |
| 4178429 | Scheffer | Dec 1979 | A |
| 4202336 | Van Gerven | May 1980 | A |
| 4266043 | Fujii et al. | May 1981 | A |
| 4269068 | Molina | May 1981 | A |
| 4381009 | Del Bon | Apr 1983 | A |
| 4396011 | Mack et al. | Aug 1983 | A |
| 4459854 | Richardson et al. | Jul 1984 | A |
| 4483341 | Witteles | Nov 1984 | A |
| 4528979 | Marchenko et al. | Jul 1985 | A |
| 4531524 | Mioduski | Jul 1985 | A |
| 4548212 | Leung | Oct 1985 | A |
| 4555313 | Duchane et al. | Nov 1985 | A |
| 4585002 | Kissin | Apr 1986 | A |
| 4603076 | Bowditch et al. | Jul 1986 | A |
| 4614191 | Perler et al. | Sep 1986 | A |
| 4644955 | Mioduski | Feb 1987 | A |
| 4664110 | Schanzlin | May 1987 | A |
| 4700701 | Montaldi | Oct 1987 | A |
| 4718429 | Smidt | Jan 1988 | A |
| 4741338 | Miyamae | May 1988 | A |
| 4764463 | Mason et al. | Aug 1988 | A |
| 4802475 | Weshahy | Feb 1989 | A |
| 4832022 | Tjulkov et al. | May 1989 | A |
| 4846176 | Golden | Jul 1989 | A |
| 4850340 | Onishi | Jul 1989 | A |
| 4869250 | Bitterly | Sep 1989 | A |
| 4880564 | Abel et al. | Nov 1989 | A |
| 4905697 | Heggs et al. | Mar 1990 | A |
| 4906463 | Cleary et al. | Mar 1990 | A |
| 4930317 | Klein | Jun 1990 | A |
| 4935345 | Guilbeau et al. | Jun 1990 | A |
| 4961422 | Marchosky et al. | Oct 1990 | A |
| 4962761 | Golden | Oct 1990 | A |
| 4990144 | Blott et al. | Feb 1991 | A |
| 5007433 | Hermsdoerffer et al. | Apr 1991 | A |
| 5018521 | Campbell et al. | May 1991 | A |
| 5024650 | Hagiwara et al. | Jun 1991 | A |
| 5065752 | Sessions et al. | Nov 1991 | A |
| 5069208 | Noppel et al. | Dec 1991 | A |
| 5084671 | Miyata et al. | Jan 1992 | A |
| 5108390 | Potocky et al. | Apr 1992 | A |
| 5119674 | Nielsen | Jun 1992 | A |
| 5143063 | Fellner | Sep 1992 | A |
| 5148804 | Hill et al. | Sep 1992 | A |
| 5158070 | Dory | Oct 1992 | A |
| 5169384 | Bosniak et al. | Dec 1992 | A |
| 5197466 | Marchosky et al. | Mar 1993 | A |
| 5207674 | Hamilton | May 1993 | A |
| 5221726 | Dabi et al. | Jun 1993 | A |
| 5264234 | Windhab et al. | Nov 1993 | A |
| 5277030 | Miller | Jan 1994 | A |
| 5314423 | Seney et al. | May 1994 | A |
| 5327886 | Chiu | Jul 1994 | A |
| 5330745 | Mcdow et al. | Jul 1994 | A |
| 5333460 | Lewis et al. | Aug 1994 | A |
| 5334131 | Omandam et al. | Aug 1994 | A |
| 5336616 | Livesey et al. | Aug 1994 | A |
| 5339541 | Owens | Aug 1994 | A |
| 5342617 | Gold et al. | Aug 1994 | A |
| 5351677 | Kami et al. | Oct 1994 | A |
| 5358467 | Milstein et al. | Oct 1994 | A |
| 5362966 | Rosenthal et al. | Nov 1994 | A |
| 5363347 | Nguyen | Nov 1994 | A |
| 5372608 | Johnson | Dec 1994 | A |
| 5386837 | Sterzer | Feb 1995 | A |
| 5411541 | Bell et al. | May 1995 | A |
| 5427772 | Hagan et al. | Jun 1995 | A |
| 5433717 | Rubinsky et al. | Jul 1995 | A |
| 5456703 | Beeuwkes, III et al. | Oct 1995 | A |
| 5472416 | Blugerman et al. | Dec 1995 | A |
| 5486207 | Mahawili | Jan 1996 | A |
| 5497596 | Zatkulak | Mar 1996 | A |
| 5501655 | Rolt et al. | Mar 1996 | A |
| 5505726 | Meserol | Apr 1996 | A |
| 5505730 | Edwards et al. | Apr 1996 | A |
| 5507790 | Weiss | Apr 1996 | A |
| 5514105 | Goodman, Jr. et al. | May 1996 | A |
| 5514170 | Mauch | May 1996 | A |
| 5531742 | Barken | Jul 1996 | A |
| 5562604 | Yablon et al. | Oct 1996 | A |
| 5571801 | Segall et al. | Nov 1996 | A |
| 5575812 | Owens et al. | Nov 1996 | A |
| 5603221 | Maytal | Feb 1997 | A |
| 5628769 | Saringer | May 1997 | A |
| 5634890 | Morris | Jun 1997 | A |
| 5634940 | Panyard | Jun 1997 | A |
| 5647051 | Neer | Jul 1997 | A |
| 5647868 | Chinn | Jul 1997 | A |
| 5650450 | Lovette et al. | Jul 1997 | A |
| 5651773 | Perry et al. | Jul 1997 | A |
| 5654279 | Rubinsky et al. | Aug 1997 | A |
| 5654546 | Lindsay et al. | Aug 1997 | A |
| 5660836 | Knowlton et al. | Aug 1997 | A |
| 5665053 | Jacobs | Sep 1997 | A |
| 5672172 | Zupkas | Sep 1997 | A |
| 5700284 | Owens et al. | Dec 1997 | A |
| 5725483 | Podolsky | Mar 1998 | A |
| 5733280 | Avitall | Mar 1998 | A |
| 5741248 | Stern et al. | Apr 1998 | A |
| 5746736 | Tankovich | May 1998 | A |
| 5755663 | Larsen et al. | May 1998 | A |
| 5755753 | Knowlton et al. | May 1998 | A |
| 5755755 | Panyard | May 1998 | A |
| 5759182 | Varney et al. | Jun 1998 | A |
| 5759764 | Polovina et al. | Jun 1998 | A |
| 5769879 | Richards et al. | Jun 1998 | A |
| 5785955 | Fischer | Jul 1998 | A |
| 5792080 | Ookawa et al. | Aug 1998 | A |
| 5800490 | Patz et al. | Sep 1998 | A |
| 5814040 | Nelson et al. | Sep 1998 | A |
| 5817050 | Klein et al. | Oct 1998 | A |
| 5817149 | Owens et al. | Oct 1998 | A |
| 5817150 | Owens et al. | Oct 1998 | A |
| 5830208 | Muller et al. | Nov 1998 | A |
| 5833685 | Tortal et al. | Nov 1998 | A |
| 5844013 | Kenndoff et al. | Dec 1998 | A |
| 5865841 | Kolen et al. | Feb 1999 | A |
| 5871524 | Knowlton | Feb 1999 | A |
| 5871526 | Gibbs et al. | Feb 1999 | A |
| 5885211 | Eppstein et al. | Mar 1999 | A |
| 5891617 | Watson et al. | Apr 1999 | A |
| 5895418 | Saringer | Apr 1999 | A |
| 5901707 | Goncalves | May 1999 | A |
| 5902256 | Benaron | May 1999 | A |
| 5919219 | Knowlton et al. | Jul 1999 | A |
| 5944748 | Mager et al. | Aug 1999 | A |
| 5948011 | Knowlton et al. | Sep 1999 | A |
| 5954680 | Augustine et al. | Sep 1999 | A |
| 5964092 | Tozuka et al. | Oct 1999 | A |
| 5964749 | Eckhouse et al. | Oct 1999 | A |
| 5967976 | Larsen et al. | Oct 1999 | A |
| 5980561 | Kolen et al. | Nov 1999 | A |
| 5986167 | Arteman et al. | Nov 1999 | A |
| 5989286 | Owens et al. | Nov 1999 | A |
| 5997530 | Nelson et al. | Dec 1999 | A |
| 6017337 | Pira | Jan 2000 | A |
| 6023932 | Johnston | Feb 2000 | A |
| 6032675 | Rubinsky | Mar 2000 | A |
| 6039694 | Larson et al. | Mar 2000 | A |
| 6041787 | Rubinsky | Mar 2000 | A |
| 6047215 | McClure et al. | Apr 2000 | A |
| 6049927 | Thomas et al. | Apr 2000 | A |
| 6051159 | Hao et al. | Apr 2000 | A |
| 6071239 | Cribbs et al. | Jun 2000 | A |
| 6074415 | Der Ovanesian | Jun 2000 | A |
| 6093230 | Johnson et al. | Jul 2000 | A |
| 6102885 | Bass | Aug 2000 | A |
| 6104952 | Tu et al. | Aug 2000 | A |
| 6104959 | Spertell et al. | Aug 2000 | A |
| 6106517 | Zupkas | Aug 2000 | A |
| 6113558 | Rosenschein et al. | Sep 2000 | A |
| 6113559 | Klopotek | Sep 2000 | A |
| 6113626 | Clifton et al. | Sep 2000 | A |
| 6120519 | Weber et al. | Sep 2000 | A |
| 6139544 | Mikus et al. | Oct 2000 | A |
| 6150148 | Nanda et al. | Nov 2000 | A |
| 6152952 | Owens et al. | Nov 2000 | A |
| 6171301 | Nelson et al. | Jan 2001 | B1 |
| 6180867 | Hedengren et al. | Jan 2001 | B1 |
| 6226996 | Weber et al. | May 2001 | B1 |
| 6241753 | Knowlton | Jun 2001 | B1 |
| 6264649 | Whitcroft et al. | Jul 2001 | B1 |
| 6273884 | Altshuler et al. | Aug 2001 | B1 |
| 6290988 | Van Vilsteren et al. | Sep 2001 | B1 |
| 6311090 | Knowlton | Oct 2001 | B1 |
| 6311497 | Chung | Nov 2001 | B1 |
| 6312453 | Stefanile et al. | Nov 2001 | B1 |
| 6350276 | Knowlton | Feb 2002 | B1 |
| 6354297 | Eiseman | Mar 2002 | B1 |
| 6357907 | Cleveland et al. | Mar 2002 | B1 |
| 6375673 | Clifton et al. | Apr 2002 | B1 |
| 6377854 | Knowlton | Apr 2002 | B1 |
| 6377855 | Knowlton | Apr 2002 | B1 |
| 6381497 | Knowlton | Apr 2002 | B1 |
| 6381498 | Knowlton | Apr 2002 | B1 |
| 6387380 | Knowlton | May 2002 | B1 |
| 6401722 | Krag | Jun 2002 | B1 |
| 6405090 | Knowlton | Jun 2002 | B1 |
| 6413255 | Stern | Jul 2002 | B1 |
| 6425912 | Knowlton | Jul 2002 | B1 |
| 6426445 | Young et al. | Jul 2002 | B1 |
| 6430446 | Knowlton | Aug 2002 | B1 |
| 6430956 | Haas et al. | Aug 2002 | B1 |
| 6438424 | Knowlton | Aug 2002 | B1 |
| 6438954 | Goetz et al. | Aug 2002 | B1 |
| 6438964 | Giblin | Aug 2002 | B1 |
| 6453202 | Knowlton | Sep 2002 | B1 |
| 6458888 | Hood et al. | Oct 2002 | B1 |
| 6461378 | Knowlton | Oct 2002 | B1 |
| 6470216 | Knowlton | Oct 2002 | B1 |
| 6471693 | Carroll et al. | Oct 2002 | B1 |
| 6475211 | Chess et al. | Nov 2002 | B2 |
| 6478811 | Dobak, III et al. | Nov 2002 | B1 |
| 6494844 | Van Bladel et al. | Dec 2002 | B1 |
| 6497721 | Ginsburg et al. | Dec 2002 | B2 |
| 6508831 | Kushnir | Jan 2003 | B1 |
| 6514244 | Pope et al. | Feb 2003 | B2 |
| 6519964 | Bieberich | Feb 2003 | B2 |
| 6523354 | Tolbert | Feb 2003 | B1 |
| 6527765 | Kelman et al. | Mar 2003 | B2 |
| 6527798 | Ginsburg et al. | Mar 2003 | B2 |
| 6544248 | Bass | Apr 2003 | B1 |
| 6547811 | Becker et al. | Apr 2003 | B1 |
| 6548297 | Kuri-Harcuch et al. | Apr 2003 | B1 |
| 6551255 | Van Bladel et al. | Apr 2003 | B2 |
| 6551341 | Boylan et al. | Apr 2003 | B2 |
| 6551348 | Blalock et al. | Apr 2003 | B1 |
| 6551349 | Lasheras et al. | Apr 2003 | B2 |
| 6569189 | Augustine et al. | May 2003 | B1 |
| 6585652 | Lang et al. | Jul 2003 | B2 |
| 6592577 | Abboud et al. | Jul 2003 | B2 |
| 6605080 | Altshuler et al. | Aug 2003 | B1 |
| 6607498 | Eshel | Aug 2003 | B2 |
| 6620187 | Carson et al. | Sep 2003 | B2 |
| 6620188 | Ginsburg et al. | Sep 2003 | B1 |
| 6620189 | Machold et al. | Sep 2003 | B1 |
| 6623430 | Slayton et al. | Sep 2003 | B1 |
| 6626854 | Friedman et al. | Sep 2003 | B2 |
| 6632219 | Baranov et al. | Oct 2003 | B1 |
| 6635053 | Lalonde et al. | Oct 2003 | B1 |
| 6643535 | Damasco et al. | Nov 2003 | B2 |
| 6645162 | Friedman et al. | Nov 2003 | B2 |
| 6645229 | Matsumura et al. | Nov 2003 | B2 |
| 6645232 | Carson | Nov 2003 | B2 |
| 6648904 | Altshuler et al. | Nov 2003 | B2 |
| 6656208 | Grahn et al. | Dec 2003 | B2 |
| 6660027 | Gruszecki et al. | Dec 2003 | B2 |
| 6662054 | Kreindel et al. | Dec 2003 | B2 |
| 6682550 | Clifton et al. | Jan 2004 | B2 |
| 6685731 | Kushnir et al. | Feb 2004 | B2 |
| 6694170 | Mikus et al. | Feb 2004 | B1 |
| 6695874 | Machold et al. | Feb 2004 | B2 |
| 6697670 | Chornenky | Feb 2004 | B2 |
| 6699237 | Weber et al. | Mar 2004 | B2 |
| 6699266 | Lachenbruch et al. | Mar 2004 | B2 |
| 6699267 | Voorhees et al. | Mar 2004 | B2 |
| 6718785 | Bieberich | Apr 2004 | B2 |
| 6741895 | Gafni et al. | May 2004 | B1 |
| 6743222 | Durkin et al. | Jun 2004 | B2 |
| 6746474 | Saadat | Jun 2004 | B2 |
| 6749624 | Knowlton | Jun 2004 | B2 |
| 6764493 | Weber et al. | Jul 2004 | B1 |
| 6764502 | Bieberich | Jul 2004 | B2 |
| 6789545 | Littrup et al. | Sep 2004 | B2 |
| 6795728 | Chornenky et al. | Sep 2004 | B2 |
| 6820961 | Johnson | Nov 2004 | B2 |
| 6821274 | McHale et al. | Nov 2004 | B2 |
| 6840955 | Ein | Jan 2005 | B2 |
| 6849075 | Bertolero et al. | Feb 2005 | B2 |
| 6878144 | Altshuler et al. | Apr 2005 | B2 |
| 6889090 | Kreindel | May 2005 | B2 |
| 6892099 | Jaafar et al. | May 2005 | B2 |
| 6904956 | Noel | Jun 2005 | B2 |
| 6918903 | Bass | Jul 2005 | B2 |
| 6927316 | Faries, Jr. et al. | Aug 2005 | B1 |
| 6942022 | Blangetti et al. | Sep 2005 | B2 |
| 6945942 | Van Bladel et al. | Sep 2005 | B2 |
| 6948903 | Ablabutyan et al. | Sep 2005 | B2 |
| 6969399 | Schock et al. | Nov 2005 | B2 |
| 7005558 | Johansson et al. | Feb 2006 | B1 |
| 7006874 | Knowlton et al. | Feb 2006 | B2 |
| 7022121 | Stern et al. | Apr 2006 | B2 |
| 7037326 | Lee | May 2006 | B2 |
| 7054685 | Dimmer et al. | May 2006 | B2 |
| 7060061 | Altshuler et al. | Jun 2006 | B2 |
| 7077858 | Fletcher et al. | Jul 2006 | B2 |
| 7081111 | Svaasand et al. | Jul 2006 | B2 |
| 7083612 | Littrup et al. | Aug 2006 | B2 |
| 7096204 | Chen et al. | Aug 2006 | B1 |
| 7112712 | Ancell | Sep 2006 | B1 |
| 7115123 | Knowlton et al. | Oct 2006 | B2 |
| 7141049 | Stern et al. | Nov 2006 | B2 |
| 7183360 | Daniel et al. | Feb 2007 | B2 |
| 7189252 | Krueger | Mar 2007 | B2 |
| 7192426 | Baust et al. | Mar 2007 | B2 |
| 7204832 | Altshuler et al. | Apr 2007 | B2 |
| 7220778 | Anderson et al. | May 2007 | B2 |
| 7229436 | Stern et al. | Jun 2007 | B2 |
| 7258674 | Cribbs et al. | Aug 2007 | B2 |
| 7267675 | Stern et al. | Sep 2007 | B2 |
| 7276058 | Altshuler et al. | Oct 2007 | B2 |
| 7318821 | Lalonde et al. | Jan 2008 | B2 |
| 7331951 | Eshel et al. | Feb 2008 | B2 |
| 7347855 | Eshel et al. | Mar 2008 | B2 |
| 7367341 | Anderson et al. | May 2008 | B2 |
| 7532201 | Quistgaard et al. | May 2009 | B2 |
| 7572268 | Babaev | Aug 2009 | B2 |
| 7604632 | Howlett et al. | Oct 2009 | B2 |
| 7613523 | Eggers et al. | Nov 2009 | B2 |
| 7615016 | Barthe et al. | Nov 2009 | B2 |
| 7713266 | Elkins et al. | May 2010 | B2 |
| 7780656 | Tankovich | Aug 2010 | B2 |
| 7799018 | Goulko | Sep 2010 | B2 |
| 7824437 | Saunders | Nov 2010 | B1 |
| 7828831 | Tanhehco et al. | Nov 2010 | B1 |
| 7850683 | Elkins et al. | Dec 2010 | B2 |
| 7854754 | Ting et al. | Dec 2010 | B2 |
| 7862558 | Elkins et al. | Jan 2011 | B2 |
| RE42277 | Jaafar et al. | Apr 2011 | E |
| 7938824 | Chornenky et al. | May 2011 | B2 |
| 7959657 | Harsy et al. | Jun 2011 | B1 |
| 7963959 | Da Silva et al. | Jun 2011 | B2 |
| 7967763 | Deem et al. | Jun 2011 | B2 |
| 7993330 | Goulko | Aug 2011 | B2 |
| 7998137 | Elkins et al. | Aug 2011 | B2 |
| RE42835 | Chornenky et al. | Oct 2011 | E |
| RE43009 | Chornenky et al. | Dec 2011 | E |
| 8133180 | Slayton et al. | Mar 2012 | B2 |
| 8133191 | Rosenberg et al. | Mar 2012 | B2 |
| 8192474 | Levinson | Jun 2012 | B2 |
| 8246611 | Paithankar et al. | Aug 2012 | B2 |
| 8275442 | Allison | Sep 2012 | B2 |
| 8285390 | Levinson et al. | Oct 2012 | B2 |
| 8333700 | Barthe et al. | Dec 2012 | B1 |
| 8337539 | Ting et al. | Dec 2012 | B2 |
| 8366622 | Slayton et al. | Feb 2013 | B2 |
| 8397518 | Vistakula et al. | Mar 2013 | B1 |
| 8414631 | Quisenberry et al. | Apr 2013 | B2 |
| 8433400 | Prushinskaya et al. | Apr 2013 | B2 |
| 8506486 | Slayton et al. | Aug 2013 | B2 |
| 8523775 | Barthe et al. | Sep 2013 | B2 |
| 8523791 | Castel | Sep 2013 | B2 |
| 8523927 | Levinson et al. | Sep 2013 | B2 |
| 8535228 | Slayton et al. | Sep 2013 | B2 |
| 8603073 | Allison | Dec 2013 | B2 |
| 8636665 | Slayton et al. | Jan 2014 | B2 |
| 8641622 | Barthe et al. | Feb 2014 | B2 |
| 8663112 | Slayton et al. | Mar 2014 | B2 |
| 8672848 | Slayton et al. | Mar 2014 | B2 |
| 8676332 | Fahey | Mar 2014 | B2 |
| 8690778 | Slayton et al. | Apr 2014 | B2 |
| 8690779 | Slayton et al. | Apr 2014 | B2 |
| 8690780 | Slayton et al. | Apr 2014 | B2 |
| 8702774 | Baker et al. | Apr 2014 | B2 |
| 8758215 | Legendre et al. | Jun 2014 | B2 |
| 8764693 | Graham et al. | Jul 2014 | B1 |
| 8834547 | Anderson et al. | Sep 2014 | B2 |
| 20010005791 | Ginsburg et al. | Jun 2001 | A1 |
| 20010007952 | Shimizu | Jul 2001 | A1 |
| 20010023364 | Ahn | Sep 2001 | A1 |
| 20010031459 | Fahy et al. | Oct 2001 | A1 |
| 20010039439 | Elkins et al. | Nov 2001 | A1 |
| 20010045104 | Bailey, Sr. et al. | Nov 2001 | A1 |
| 20010047196 | Ginsburg et al. | Nov 2001 | A1 |
| 20020026226 | Ein | Feb 2002 | A1 |
| 20020032473 | Kushnir et al. | Mar 2002 | A1 |
| 20020049483 | Knowlton | Apr 2002 | A1 |
| 20020058975 | Bieberich | May 2002 | A1 |
| 20020062142 | Knowlton | May 2002 | A1 |
| 20020068338 | Nanda et al. | Jun 2002 | A1 |
| 20020082668 | Ingman | Jun 2002 | A1 |
| 20020103520 | Latham | Aug 2002 | A1 |
| 20020107558 | Clifton et al. | Aug 2002 | A1 |
| 20020117293 | Campbell | Aug 2002 | A1 |
| 20020120315 | Furuno et al. | Aug 2002 | A1 |
| 20020128648 | Weber et al. | Sep 2002 | A1 |
| 20020151830 | Kahn | Oct 2002 | A1 |
| 20020151887 | Stern et al. | Oct 2002 | A1 |
| 20020156509 | Cheung | Oct 2002 | A1 |
| 20020188286 | Quijano et al. | Dec 2002 | A1 |
| 20020198518 | Mikus et al. | Dec 2002 | A1 |
| 20030032900 | Ella | Feb 2003 | A1 |
| 20030044764 | Soane et al. | Mar 2003 | A1 |
| 20030055414 | Altshuler et al. | Mar 2003 | A1 |
| 20030069618 | Smith, III et al. | Apr 2003 | A1 |
| 20030077326 | Newton et al. | Apr 2003 | A1 |
| 20030077329 | Kipp et al. | Apr 2003 | A1 |
| 20030079488 | Bieberich | May 2003 | A1 |
| 20030100936 | Altshuler et al. | May 2003 | A1 |
| 20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
| 20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
| 20030109911 | Lachenbruch et al. | Jun 2003 | A1 |
| 20030114885 | Nova et al. | Jun 2003 | A1 |
| 20030120268 | Bertolero et al. | Jun 2003 | A1 |
| 20030125649 | McIntosh et al. | Jul 2003 | A1 |
| 20030187488 | Kreindel et al. | Oct 2003 | A1 |
| 20030199226 | Sommer et al. | Oct 2003 | A1 |
| 20030199859 | Altshuler et al. | Oct 2003 | A1 |
| 20030220594 | Halvorson et al. | Nov 2003 | A1 |
| 20030220635 | Knowlton et al. | Nov 2003 | A1 |
| 20030220674 | Anderson et al. | Nov 2003 | A1 |
| 20030236487 | Knowlton | Dec 2003 | A1 |
| 20040002705 | Knowlton et al. | Jan 2004 | A1 |
| 20040006328 | Anderson | Jan 2004 | A1 |
| 20040009936 | Tang et al. | Jan 2004 | A1 |
| 20040024437 | Machold et al. | Feb 2004 | A1 |
| 20040030332 | Knowlton et al. | Feb 2004 | A1 |
| 20040034341 | Altshuler et al. | Feb 2004 | A1 |
| 20040039312 | Hillstead et al. | Feb 2004 | A1 |
| 20040044384 | Leber et al. | Mar 2004 | A1 |
| 20040049178 | Abboud et al. | Mar 2004 | A1 |
| 20040073079 | Altshuler et al. | Apr 2004 | A1 |
| 20040074629 | Noel | Apr 2004 | A1 |
| 20040077977 | Ella et al. | Apr 2004 | A1 |
| 20040082886 | Timpson | Apr 2004 | A1 |
| 20040093042 | Altshuler et al. | May 2004 | A1 |
| 20040104012 | Zhou et al. | Jun 2004 | A1 |
| 20040106867 | Eshel et al. | Jun 2004 | A1 |
| 20040162596 | Altshuler et al. | Aug 2004 | A1 |
| 20040176667 | Mihai et al. | Sep 2004 | A1 |
| 20040186535 | Knowlton | Sep 2004 | A1 |
| 20040199226 | Shadduck | Oct 2004 | A1 |
| 20040206365 | Knowlton | Oct 2004 | A1 |
| 20040210214 | Knowlton | Oct 2004 | A1 |
| 20040210287 | Greene | Oct 2004 | A1 |
| 20040215294 | Littrup et al. | Oct 2004 | A1 |
| 20040249427 | Nabilsi et al. | Dec 2004 | A1 |
| 20040259855 | Anderson et al. | Dec 2004 | A1 |
| 20040260209 | Ella et al. | Dec 2004 | A1 |
| 20040260210 | Ella et al. | Dec 2004 | A1 |
| 20040260211 | Maalouf | Dec 2004 | A1 |
| 20050033957 | Enokida | Feb 2005 | A1 |
| 20050049526 | Baer | Mar 2005 | A1 |
| 20050049543 | Anderson et al. | Mar 2005 | A1 |
| 20050049661 | Koffroth | Mar 2005 | A1 |
| 20050113725 | Masuda | May 2005 | A1 |
| 20050143781 | Carbunaru et al. | Jun 2005 | A1 |
| 20050145372 | Noel | Jul 2005 | A1 |
| 20050154314 | Quistgaard | Jul 2005 | A1 |
| 20050154431 | Quistgaard et al. | Jul 2005 | A1 |
| 20050159986 | Breeland et al. | Jul 2005 | A1 |
| 20050182462 | Chornenky et al. | Aug 2005 | A1 |
| 20050187495 | Quistgaard et al. | Aug 2005 | A1 |
| 20050187597 | Vanderschuit | Aug 2005 | A1 |
| 20050203446 | Takashima | Sep 2005 | A1 |
| 20050215987 | Slatkine | Sep 2005 | A1 |
| 20050222565 | Manstein | Oct 2005 | A1 |
| 20050251117 | Anderson et al. | Nov 2005 | A1 |
| 20050251120 | Anderson et al. | Nov 2005 | A1 |
| 20050261753 | Littrup et al. | Nov 2005 | A1 |
| 20050283144 | Shiono et al. | Dec 2005 | A1 |
| 20060030778 | Mendlein et al. | Feb 2006 | A1 |
| 20060035380 | Saint-Leger | Feb 2006 | A1 |
| 20060036300 | Kreindel | Feb 2006 | A1 |
| 20060041704 | Choi | Feb 2006 | A1 |
| 20060074313 | Slayton et al. | Apr 2006 | A1 |
| 20060079852 | Bubb et al. | Apr 2006 | A1 |
| 20060094988 | Tosaya et al. | May 2006 | A1 |
| 20060106836 | Masugi et al. | May 2006 | A1 |
| 20060122509 | Desilets | Jun 2006 | A1 |
| 20060189964 | Anderson et al. | Aug 2006 | A1 |
| 20060195168 | Dunbar et al. | Aug 2006 | A1 |
| 20060200063 | Munro et al. | Sep 2006 | A1 |
| 20060206040 | Greenberg et al. | Sep 2006 | A1 |
| 20060206110 | Knowlton et al. | Sep 2006 | A1 |
| 20060234899 | Nekmard et al. | Oct 2006 | A1 |
| 20060259102 | Slatkine | Nov 2006 | A1 |
| 20060265032 | Hennings et al. | Nov 2006 | A1 |
| 20060270745 | Hunt et al. | Nov 2006 | A1 |
| 20060293734 | Scott et al. | Dec 2006 | A1 |
| 20070010811 | Stern et al. | Jan 2007 | A1 |
| 20070010861 | Anderson et al. | Jan 2007 | A1 |
| 20070032561 | Lin et al. | Feb 2007 | A1 |
| 20070038156 | Rosenberg | Feb 2007 | A1 |
| 20070055156 | Desilets et al. | Mar 2007 | A1 |
| 20070055173 | DeLonzor et al. | Mar 2007 | A1 |
| 20070055179 | Deem et al. | Mar 2007 | A1 |
| 20070055180 | Deem et al. | Mar 2007 | A1 |
| 20070055181 | Deem et al. | Mar 2007 | A1 |
| 20070078502 | Weber et al. | Apr 2007 | A1 |
| 20070100398 | Sloan | May 2007 | A1 |
| 20070106342 | Schumann | May 2007 | A1 |
| 20070129714 | Elkins et al. | Jun 2007 | A1 |
| 20070135876 | Weber | Jun 2007 | A1 |
| 20070141265 | Thomson | Jun 2007 | A1 |
| 20070179482 | Anderson et al. | Aug 2007 | A1 |
| 20070198071 | Ting et al. | Aug 2007 | A1 |
| 20070219540 | Masotti et al. | Sep 2007 | A1 |
| 20070239075 | Rosenberg et al. | Oct 2007 | A1 |
| 20070239150 | Zvuloni et al. | Oct 2007 | A1 |
| 20070249519 | Guha et al. | Oct 2007 | A1 |
| 20070255187 | Branch | Nov 2007 | A1 |
| 20070255274 | Stern et al. | Nov 2007 | A1 |
| 20070255362 | Levinson et al. | Nov 2007 | A1 |
| 20070265585 | Joshi et al. | Nov 2007 | A1 |
| 20070265614 | Stern et al. | Nov 2007 | A1 |
| 20070270925 | Levinson | Nov 2007 | A1 |
| 20070282249 | Quisenberry et al. | Dec 2007 | A1 |
| 20070282318 | Spooner et al. | Dec 2007 | A1 |
| 20080014627 | Merchant et al. | Jan 2008 | A1 |
| 20080046047 | Jacobs | Feb 2008 | A1 |
| 20080058784 | Manstein et al. | Mar 2008 | A1 |
| 20080077201 | Levinson et al. | Mar 2008 | A1 |
| 20080077202 | Levinson | Mar 2008 | A1 |
| 20080077211 | Levinson et al. | Mar 2008 | A1 |
| 20080139901 | Altshuler et al. | Jun 2008 | A1 |
| 20080140061 | Toubia et al. | Jun 2008 | A1 |
| 20080140371 | Warner | Jun 2008 | A1 |
| 20080183164 | Elkins et al. | Jul 2008 | A1 |
| 20080188915 | Mills et al. | Aug 2008 | A1 |
| 20080248554 | Merchant et al. | Oct 2008 | A1 |
| 20080269851 | Deem et al. | Oct 2008 | A1 |
| 20080287839 | Rosen et al. | Nov 2008 | A1 |
| 20080312651 | Pope et al. | Dec 2008 | A1 |
| 20090012434 | Anderson | Jan 2009 | A1 |
| 20090018623 | Levinson et al. | Jan 2009 | A1 |
| 20090018624 | Levinson et al. | Jan 2009 | A1 |
| 20090018625 | Levinson et al. | Jan 2009 | A1 |
| 20090018626 | Levinson et al. | Jan 2009 | A1 |
| 20090018627 | Levinson et al. | Jan 2009 | A1 |
| 20090024023 | Welches et al. | Jan 2009 | A1 |
| 20090076488 | Welches et al. | Mar 2009 | A1 |
| 20090112134 | Avni | Apr 2009 | A1 |
| 20090118722 | Ebbers et al. | May 2009 | A1 |
| 20090149929 | Levinson et al. | Jun 2009 | A1 |
| 20090149930 | Schenck | Jun 2009 | A1 |
| 20090171253 | Davenport | Jul 2009 | A1 |
| 20090171334 | Elkins et al. | Jul 2009 | A1 |
| 20090221938 | Rosenberg et al. | Sep 2009 | A1 |
| 20090276018 | Brader | Nov 2009 | A1 |
| 20090281464 | Cioanta et al. | Nov 2009 | A1 |
| 20090306749 | Mulindwa | Dec 2009 | A1 |
| 20090312676 | Rousso et al. | Dec 2009 | A1 |
| 20090312693 | Thapliyal et al. | Dec 2009 | A1 |
| 20090326621 | El-Galley | Dec 2009 | A1 |
| 20100015190 | Hassler | Jan 2010 | A1 |
| 20100028969 | Mueller et al. | Feb 2010 | A1 |
| 20100030306 | Edelman et al. | Feb 2010 | A1 |
| 20100036295 | Altshuler et al. | Feb 2010 | A1 |
| 20100049178 | Deem et al. | Feb 2010 | A1 |
| 20100081971 | Allison | Apr 2010 | A1 |
| 20100087806 | Da Silva et al. | Apr 2010 | A1 |
| 20100152824 | Allison | Jun 2010 | A1 |
| 20100168726 | Brookman | Jul 2010 | A1 |
| 20100179531 | Nebrigic et al. | Jul 2010 | A1 |
| 20100198064 | Perl et al. | Aug 2010 | A1 |
| 20100217349 | Fahey et al. | Aug 2010 | A1 |
| 20100268220 | Johnson et al. | Oct 2010 | A1 |
| 20100280582 | Baker et al. | Nov 2010 | A1 |
| 20110009860 | Chornenky et al. | Jan 2011 | A1 |
| 20110040235 | Castel | Feb 2011 | A1 |
| 20110040299 | Kim et al. | Feb 2011 | A1 |
| 20110046523 | Altshuler et al. | Feb 2011 | A1 |
| 20110060323 | Baust et al. | Mar 2011 | A1 |
| 20110066083 | Tosaya et al. | Mar 2011 | A1 |
| 20110066216 | Ting et al. | Mar 2011 | A1 |
| 20110077557 | Wing et al. | Mar 2011 | A1 |
| 20110077723 | Parish et al. | Mar 2011 | A1 |
| 20110112405 | Barthe et al. | May 2011 | A1 |
| 20110112520 | Michael | May 2011 | A1 |
| 20110144631 | Elkins et al. | Jun 2011 | A1 |
| 20110152849 | Baust et al. | Jun 2011 | A1 |
| 20110172651 | Altshuler et al. | Jul 2011 | A1 |
| 20110189129 | Qiu et al. | Aug 2011 | A1 |
| 20110196395 | Maschke | Aug 2011 | A1 |
| 20110196438 | Mnozil et al. | Aug 2011 | A1 |
| 20110202048 | Nebrigic et al. | Aug 2011 | A1 |
| 20110238050 | Allison et al. | Sep 2011 | A1 |
| 20110238051 | Levinson et al. | Sep 2011 | A1 |
| 20110257642 | Griggs, III | Oct 2011 | A1 |
| 20110300079 | Martens et al. | Dec 2011 | A1 |
| 20110301585 | Goulko | Dec 2011 | A1 |
| 20110313411 | Anderson et al. | Dec 2011 | A1 |
| 20110313412 | Kim et al. | Dec 2011 | A1 |
| 20120010609 | Deem et al. | Jan 2012 | A1 |
| 20120016239 | Barthe et al. | Jan 2012 | A1 |
| 20120022518 | Levinson | Jan 2012 | A1 |
| 20120022622 | Johnson et al. | Jan 2012 | A1 |
| 20120035475 | Barthe et al. | Feb 2012 | A1 |
| 20120035476 | Barthe et al. | Feb 2012 | A1 |
| 20120046547 | Barthe et al. | Feb 2012 | A1 |
| 20120053458 | Barthe et al. | Mar 2012 | A1 |
| 20120065629 | Elkins et al. | Mar 2012 | A1 |
| 20120083862 | Altshuler et al. | Apr 2012 | A1 |
| 20120101549 | Schumann | Apr 2012 | A1 |
| 20120109041 | Munz | May 2012 | A1 |
| 20120158100 | Schomacker | Jun 2012 | A1 |
| 20120209363 | Williams, III et al. | Aug 2012 | A1 |
| 20120239123 | Weber et al. | Sep 2012 | A1 |
| 20120253416 | Erez et al. | Oct 2012 | A1 |
| 20120259322 | Fourkas et al. | Oct 2012 | A1 |
| 20120277674 | Clark, III et al. | Nov 2012 | A1 |
| 20120310232 | Erez | Dec 2012 | A1 |
| 20130018236 | Altshuler et al. | Jan 2013 | A1 |
| 20130019374 | Schwartz | Jan 2013 | A1 |
| 20130066309 | Levinson | Mar 2013 | A1 |
| 20130073017 | Liu et al. | Mar 2013 | A1 |
| 20130079684 | Rosen et al. | Mar 2013 | A1 |
| 20130116758 | Levinson et al. | May 2013 | A1 |
| 20130116759 | Levinson et al. | May 2013 | A1 |
| 20130150844 | Deem et al. | Jun 2013 | A1 |
| 20130158440 | Allison | Jun 2013 | A1 |
| 20130158636 | Ting et al. | Jun 2013 | A1 |
| 20130166003 | Johnson et al. | Jun 2013 | A1 |
| 20130190744 | Avram et al. | Jul 2013 | A1 |
| 20130238062 | Ron Edoute et al. | Sep 2013 | A1 |
| 20130245507 | Khorassani Zadeh | Sep 2013 | A1 |
| 20130253384 | Anderson et al. | Sep 2013 | A1 |
| 20130253493 | Anderson et al. | Sep 2013 | A1 |
| 20130253494 | Anderson et al. | Sep 2013 | A1 |
| 20130253495 | Anderson et al. | Sep 2013 | A1 |
| 20130253496 | Anderson et al. | Sep 2013 | A1 |
| 20130303904 | Barthe et al. | Nov 2013 | A1 |
| 20130303905 | Barthe et al. | Nov 2013 | A1 |
| 20130331914 | Lee et al. | Dec 2013 | A1 |
| 20140005759 | Fahey et al. | Jan 2014 | A1 |
| 20140005760 | Levinson et al. | Jan 2014 | A1 |
| 20140142469 | Britva et al. | May 2014 | A1 |
| 20140200488 | Seo et al. | Jul 2014 | A1 |
| 20140222121 | Spence et al. | Aug 2014 | A1 |
| 20140277219 | Nanda | Sep 2014 | A1 |
| 20140277302 | Weber et al. | Sep 2014 | A1 |
| 20150209174 | Abreu | Jul 2015 | A1 |
| 20150216719 | Debenedictis et al. | Aug 2015 | A1 |
| 20150216720 | Debenedictis et al. | Aug 2015 | A1 |
| 20150216816 | O'Neil et al. | Aug 2015 | A1 |
| 20150328077 | Levinson | Nov 2015 | A1 |
| 20150342780 | Levinson et al. | Dec 2015 | A1 |
| 20160051308 | Pennybacker et al. | Feb 2016 | A1 |
| 20160051401 | Yee et al. | Feb 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 2011253768 | Jun 2012 | AU |
| 2441489 | Mar 2005 | CA |
| 2585214 | Oct 2007 | CA |
| 333982 | Nov 1958 | CH |
| 86200604 | Oct 1987 | CN |
| 2514795 | Oct 2002 | CN |
| 2514811 | Oct 2002 | CN |
| 1511503 | Jul 2004 | CN |
| 1741777 | Mar 2006 | CN |
| 1817990 | Aug 2006 | CN |
| 2843367 | Dec 2006 | CN |
| 2850584 | Dec 2006 | CN |
| 2850585 | Dec 2006 | CN |
| 200970265 | Nov 2007 | CN |
| 101259329 | Sep 2008 | CN |
| 101309657 | Nov 2008 | CN |
| 532976 | Sep 1931 | DE |
| 2851602 | Jun 1980 | DE |
| 4213584 | Nov 1992 | DE |
| 4224595 | Jan 1994 | DE |
| 4238291 | May 1994 | DE |
| 4445627 | Jun 1996 | DE |
| 19800416 | Jul 1999 | DE |
| 263069 | Apr 1988 | EP |
| 0397043 | Nov 1990 | EP |
| 0406244 | Jan 1991 | EP |
| 0598824 | Jun 1994 | EP |
| 1030611 | Aug 2000 | EP |
| 1201266 | May 2002 | EP |
| 1568395 | Aug 2005 | EP |
| 2260801 | Dec 2010 | EP |
| 2289598 | Mar 2011 | EP |
| 2527005 | Nov 2012 | EP |
| 854937 | Apr 1940 | FR |
| 2744358 | Aug 1997 | FR |
| 2745935 | Sep 1997 | FR |
| 2767476 | Feb 1999 | FR |
| 2776920 | Oct 1999 | FR |
| 2789893 | Aug 2000 | FR |
| 2805989 | Sep 2001 | FR |
| 387960 | Feb 1933 | GB |
| 2120944 | Dec 1983 | GB |
| 2248183 | Apr 1992 | GB |
| 2263872 | Aug 1993 | GB |
| 2286660 | Aug 1995 | GB |
| 2323659 | Sep 1998 | GB |
| 58187454 | Nov 1983 | JP |
| 62082977 | Apr 1987 | JP |
| 63076895 | Apr 1988 | JP |
| 01223961 | Sep 1989 | JP |
| 03051964 | Mar 1991 | JP |
| 03259975 | Nov 1991 | JP |
| 04093597 | Mar 1992 | JP |
| 06261933 | Sep 1994 | JP |
| 07194666 | Aug 1995 | JP |
| 07268274 | Oct 1995 | JP |
| 09164163 | Jun 1997 | JP |
| 10216169 | Aug 1998 | JP |
| 10223961 | Aug 1998 | JP |
| 2000503154 | Mar 2000 | JP |
| 3065657 | Jul 2000 | JP |
| 2001046416 | Feb 2001 | JP |
| 2002125993 | May 2002 | JP |
| 2002224051 | Aug 2002 | JP |
| 2002282295 | Oct 2002 | JP |
| 2002290397 | Oct 2002 | JP |
| 2002543668 | Dec 2002 | JP |
| 2003190201 | Jul 2003 | JP |
| 2004013600 | Jan 2004 | JP |
| 2004073812 | Mar 2004 | JP |
| 2004159666 | Jun 2004 | JP |
| 2005039790 | Feb 2005 | JP |
| 2005065984 | Mar 2005 | JP |
| 2005110755 | Apr 2005 | JP |
| 2005509977 | Apr 2005 | JP |
| 3655820 | Jun 2005 | JP |
| 2005520608 | Jul 2005 | JP |
| 2005237908 | Sep 2005 | JP |
| 2005323716 | Nov 2005 | JP |
| 2006026001 | Feb 2006 | JP |
| 2006130055 | May 2006 | JP |
| 2006520949 | Sep 2006 | JP |
| 2007270459 | Oct 2007 | JP |
| 2008532591 | Aug 2008 | JP |
| 2009515232 | Apr 2009 | JP |
| 2009189757 | Aug 2009 | JP |
| 200173222 | Dec 1999 | KR |
| 1020040094508 | Nov 2004 | KR |
| 20090000258 | Jan 2009 | KR |
| 1020130043299 | Apr 2013 | KR |
| 1020140038165 | Mar 2014 | KR |
| 2036667 | Jun 1995 | RU |
| 532976 | Nov 1978 | SU |
| 0476644 | Feb 2002 | TW |
| 8503216 | Aug 1985 | WO |
| 9114417 | Oct 1991 | WO |
| 9404116 | Mar 1994 | WO |
| 9623447 | Aug 1996 | WO |
| 9626693 | Sep 1996 | WO |
| 9636293 | Nov 1996 | WO |
| 9637158 | Nov 1996 | WO |
| 9704832 | Feb 1997 | WO |
| 9705828 | Feb 1997 | WO |
| 9722262 | Jun 1997 | WO |
| 9724088 | Jul 1997 | WO |
| 9725798 | Jul 1997 | WO |
| 9748440 | Dec 1997 | WO |
| 9829134 | Jul 1998 | WO |
| 9831321 | Jul 1998 | WO |
| 9841156 | Sep 1998 | WO |
| 9841157 | Sep 1998 | WO |
| 9909928 | Mar 1999 | WO |
| 9916502 | Apr 1999 | WO |
| 9938469 | Aug 1999 | WO |
| 9949937 | Oct 1999 | WO |
| 0044346 | Aug 2000 | WO |
| 0044349 | Aug 2000 | WO |
| 0065770 | Nov 2000 | WO |
| 0067685 | Nov 2000 | WO |
| 0100269 | Jan 2001 | WO |
| 0113989 | Mar 2001 | WO |
| 0114012 | Mar 2001 | WO |
| 0134048 | May 2001 | WO |
| 0205736 | Jan 2002 | WO |
| 02102921 | Dec 2002 | WO |
| 03007859 | Jan 2003 | WO |
| 03078596 | Sep 2003 | WO |
| 03079916 | Oct 2003 | WO |
| 04000098 | Dec 2003 | WO |
| 2004080279 | Sep 2004 | WO |
| 2004090939 | Oct 2004 | WO |
| 2005033957 | Apr 2005 | WO |
| 2005046540 | May 2005 | WO |
| 2005060354 | Jul 2005 | WO |
| 2005096979 | Oct 2005 | WO |
| 2005112815 | Dec 2005 | WO |
| 2006066226 | Jun 2006 | WO |
| 2006094348 | Sep 2006 | WO |
| 2006106836 | Oct 2006 | WO |
| 2006116603 | Nov 2006 | WO |
| 2006127467 | Nov 2006 | WO |
| 2007012083 | Jan 2007 | WO |
| 2007028975 | Mar 2007 | WO |
| 2007041642 | Apr 2007 | WO |
| 2007101039 | Sep 2007 | WO |
| 2007127924 | Nov 2007 | WO |
| 2007145421 | Dec 2007 | WO |
| 2007145422 | Dec 2007 | WO |
| 2008006018 | Jan 2008 | WO |
| 2008039556 | Apr 2008 | WO |
| 2008039557 | Apr 2008 | WO |
| 2008055243 | May 2008 | WO |
| 2008143678 | Nov 2008 | WO |
| 2009011708 | Jan 2009 | WO |
| 2009026471 | Feb 2009 | WO |
| 2010077841 | Jul 2010 | WO |
| 2010127315 | Nov 2010 | WO |
| 2012012296 | Jan 2012 | WO |
| 2012103242 | Aug 2012 | WO |
| 2013013059 | Jan 2013 | WO |
| 2013075006 | May 2013 | WO |
| 2013075016 | May 2013 | WO |
| 2013190337 | Dec 2013 | WO |
| 2014151872 | Sep 2014 | WO |
| 2015117001 | Aug 2015 | WO |
| 2015117026 | Aug 2015 | WO |
| 2015117032 | Aug 2015 | WO |
| 2015117036 | Aug 2015 | WO |
| 2016028796 | Feb 2016 | WO |
| 2016048721 | Mar 2016 | WO |
| Entry |
|---|
| “ThermaCool Monopolar Capacitive Radiofrequency, The one choice for nonablative tissue tightening and contouring” Thermage, Inc. Tech Brochure, Nov. 30, 2005, 8 pgs. |
| Aguilar, G. et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis,” Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages. |
| Al-Sakere, B. et al. “Tumor Ablation with Irreversible Electroporation,” PLoS One, Issue 11, Nov. 2007, 8 pages. |
| Alster, T. et al., “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic and Laser Therapy, vol. 7, 2005, pp. 81-85. |
| Ardevol, A. et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen,” Journal of Biochemical and Biophysical Methods, vol. 27, 1993, pp. 77-86. |
| Arena, C. B. et al., “High-Frequency Irreversible Electroporation (H-FIRE) for Non-Thermal Ablation Without Muscle Contraction,” BioMedical Engineering OnLine 2011, 10:102, Nov. 21, 2011, 21 pgs. |
| Becker, S. M. et al. “Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model,” Journal of Biomechanical Engineering, vol. 129, Oct. 2007, pp. 712-721. |
| Bohm, T. et al., “Saline-Enhanced Radiofrequency Ablation of Breast Tissue: an in Vitro Feasibility Study,” Investigative Radiology, vol. 35 (3), 2000, pp. 149-157. |
| Bondei, E. et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Fourth Edition, vol. 1, Chapter 108, 1993, Section 16, pp. 1333-1334. |
| Burge, S.M. et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2), 1990, pp. 153-163. |
| Coban, Y. K. et al., “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating Early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, pp. 304-308. |
| Del Pino, M. E. et al. “Effect of Controlled Volumetric Tissue Heating with Radiofrequency on Cellulite and the Subcutaneous Tissue of the Buttocks and Thighs,” Journal of Drugs in Dermatology, vol. 5, Issue 8, Sep. 2006, pp. 714-722. |
| Donski, P. K. et al., “The Effects of Cooling no Experimental Free Flap Survival,” British Journal of Plastic Surgery, vol. 33, 1980, pp. 353-360. |
| Duck, F. A., Physical Properties of Tissue, Academic Press Ltd., Chapters 4 & 5, 1990, pp. 73-165. |
| Duncan, W. C. et al., “Cold Panniculitis,” Archives of Dermatology, vol. 94, Issue 6, Dec. 1966, pp. 722-724. |
| Epstein, E. H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17), Apr. 23, 1970, pp. 966-967. |
| Fournier, L. et al. “Lattice Model for the Kinetics of Rupture of Fluid Bilayer Membranes,” Physical Review, vol. 67, 2003, pp. 051908-1-051908-11. |
| Gabriel, S. et al., “The Dielectric Properties of Biological Tissues: II. Measurements in the Frequency Range 10 Hz to 20 GHz,” Physics in Medicine and Biology, vol. 41, 1996, pp. 2251-2269. |
| Gage, A. “Current Progress in Cryosurgery,” Cryobiology 25, 1988, pp. 483-486. |
| Gatto, H. “Effects of Thermal Shocks on Interleukin-1 Levels and Heat Shock Protein 72 (HSP72) Expression in Normal Human Keratinocytes,” PubMed, Archives of Dermatological Research, vol. 284, Issue 7, 1992: pp. 414-417 [Abstract]. |
| Hale, H. B. et al., “Influence of Chronic Heat Exposure and Prolonged Food Deprivation on Excretion of Magnesium, Phosphorus, Calcium, Hydrogen Ion & Ketones,” Aerospace Medicine, vol. 39—No. 9, Sep. 1968, pp. 919-926. |
| Heller Page, E. et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, vol. 18, No. 5, Pt 1, May 1988, pp. 1003-1019. |
| Hemmingsson, A. et al. “Attenuation in Human Muscle and Fat Tissue in Vivo and in Vitro,” Acra Radiologica Diagnosis, vol. 23, No. 2, 1982, pp. 149-151. |
| Henry, F. et al., “Les Dermatoses Hivernales,” Rev Med Liege, 54:11, 1999, pp. 864-866. [Abstract Attached]. |
| Holland, DB. et al. “Cold shock induces the synthesis of stress proteins in human keratinocytes,” PubMed Journal of Investigative Dermatology; 101(2): Aug. 1993, pp. 196-199. |
| Holman, W. L. et al., “Variation in Cryolesion Penetration Due to Probe Size and Tissue Thermal Conductivity,” The Annals of Thoracic Surgery, vol. 53, 1992, pp. 123-126. |
| Hong, J.S. et al., “Patterns of Ice Formation in Normal and Malignant Breast Tissue,” Cryobiology 31, 1994, pp. 109-120. |
| Huang et al. “Comparative Proteomic Profiling of Murine Skin,” Journal of Investigative Dermatology, vol. 121(1), Jul. 2003, pp. 51-64. |
| International Search Report and Written Opinion for PCT/US2014/026558; Mailed on Oct. 24, 2014, 16 pages. |
| Isambert, H. “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Physical Review Letters, vol. 80, No. 15, 1998, pp. 3404-3707. |
| Kellum, R. E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Archives of Dermatology, vol. 97, Apr. 1968, pp. 372-380. |
| Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Annals of the New York Academy of Sciences, vol. 967, 2002,pp. 500-505. |
| Kundu, S. K. et al., “Breath Acetone Analyzer: Diagnostic Tool to Monitor Dietary Fat Loss,” Clinical Chemistry, vol. 39, Issue (1), 1993, pp. 87-92. |
| Kundu, S. K. et al., “Novel Solid-Phase Assay of Ketone Bodies in Urine,” Clinical Chemistry, vol. 37, Issue (9), 1991, pp. 1565-1569. |
| Kuroda, S. et al. “Thermal Distribution of Radio-Frequency Inductive Hyperthermia Using an Inductive Aperture-Type Applicator: Evaluation of the Effect of Tumor Size and Depth”, Medical and Biological Engineering and Computing, vol. 37, 1999, pp. 285-290. |
| Laugier, P. et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The Society for Investigative Dermatology, Inc., vol. 111, No. 2, Aug. 1998, pp. 314-319. |
| Levchenko et al., “Effect of Dehydration on Lipid Metabolism” Ukrainskii Biokhimicheskii Zhurnal, vol. 50, Issue 1, 1978, pp. 95-97. |
| Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model,” Annals of Plastic Surgery, vol. 44, No. 5, May 2000, pp. 512-515. |
| Liu, A. Y.-C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” Journal of Biological Chemistry, , 269(20), May 20, 1994, pp. 14768-14775. |
| L'Vova, S.P. “Lipid Levels and Lipid Peroxidation in Frog Tissues During Hypothermia and Hibernation” Ukrainskii Biokhimicheskii Zhurnal, vol. 62, Issue 1, 1990, pp. 65-70. |
| Maize, J.C. “Panniculitis,” Cutaneous Pathology, Chapter 13, 1998, 327-344. |
| Malcolm, G. T. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” The American Journal of Clinical Nutrition, vol. 50, 1989, pp. 288-291. |
| Manstein, D. et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis,” LasersSurg.Med 40:S20, 2008, p. 104. |
| Manstein, D. et al. “Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal,” Lasers in Surgery and Medicine: The Official Journal of the ASLMS, vol. 40, 2008, pp. 595-604. |
| Mayoral, “Case Reports: Skin Tightening with a Combined Unipolar and Bipolar Radiofrequency Device,” Journal of Drugs in Dermatology, 2007, pp. 212-215. |
| Mazur, P. “Cryobiology: the Freezing of Biological Systems,” Science, 68, 1970, pp. 939-949. |
| Merrill, T. “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010, 10 pages. |
| Miklavcic, D. et al. “Electroporation-Based Technologies and Treatments,” The Journal of Membrane Biology (2010) 236:1-2, 2 pgs. |
| Moschella, S. L. et al., “Diseases of the Subcutaneous Tissue,” in Dermatology, Second Edition, vol. 2, 1985 Chapter 19, Section II (W.B. Saunders Company, 1980) pp. 1169-1181. |
| Murphy, J. V. et al., “Frostbite: Pathogenesis and Treatment” The Journal of Trauma: Injury, Infection, and Critical Care, vol. 48, No. 1, Jan. 2000, pp. 171-178. |
| Nagao, T. et al., “Dietary Diacylglycerol Suppresses Accumulation of Body Fat Compared to Triacylglycerol in Men a Double-Blind Controlled Trial,” The Journal of Nutrition, vol. 130, Issue (4), 2000, pp. 792-797. |
| Nagle, W. A. et al. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures,” Cryobiology 27, 1990, pp. 439-451. |
| Nagore, E. et al., “Lipoatrophia Semicircularis—a Traumatic Panniculitis: Report of Seven Cases and Review of the Literature,” Journal of the American Academy of Dermatology, vol. 39, Nov. 1998, pp. 879-881. |
| Nanda, G.S. et al., “Studies on electroporation of thermally and chemically treated human erythrocytes,” Bioelectrochemistry and Bioenergetics, 34, 1994, pp. 129-134, 6 pgs. |
| Narins, D.J. et al. “Non-Surgical Radiofrequency Facelift”, The Journal of Drugs in Dermatology, vol. 2, Issue 5, 2003, pp. 495-500. |
| Nielsen, B. “Thermoregulation in Rest and Exercise,” Acta Physiologica Scandinavica Supplementum, vol. 323 (Copenhagen 1969), pp. 7-74. |
| Nishikawa, H. et al. “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, vol. 54, No. 5,1992, pp. 795-801. |
| Nurnberger, F. “So-Called Cellulite: An Invented Disease,” Journal of Dermatologic Surgery and Oncology, Mar. 1978, pp. 221-229. |
| Pease, G. R. et al., “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering, vol. 117, Feb. 1995, pp. 59-63. |
| Pech, P. et al., “Attenuation Values, Volume Changes and Artifacts in Tissue Due to Freezing,” Acta Radiologica ,vol. 28, Issue 6, 1987, pp. 779-782. |
| Peterson, L. J. et al., “Bilateral Fat Necrosis of the Scrotum,” Journal of Urology, vol. 116, 1976, pp. 825-826. |
| Phinney, S. D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” The American Journal of Clinical Nutrition, vol. 60, 1994, pp. 725-729. |
| Pierard, G.E. et al., “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” The American Journal of Dermatology, vol. 22, Issue 1, 2000, pp. 34-37, [Abstract]. |
| Pope, K. et al. “Selective Fibrous Septae Heating: An Additional Mechanism of Action for Capacitively Coupled Monopolar Radiofrequency” Thermage, Inc. Article, Feb. 2005, 6pgs. |
| Quinn, P. J. “A Lipid-Phase Separation Model of Low-Temperature Damage to Biological Membranes,” Cryobiology, 22, 1985, 128-146. |
| Rabi, T. et al., “Metabolic Adaptations in Brown Adipose Tissue of the Hamster in Extreme Ambient Temperatures,” American Journal of Physiology, vol. 231, Issue 1, Jul. 1976, pp. 153-160. |
| Renold, A.E. et al. “Adipose Tissue” in Handbook of Physiology, Chapter 15, (Washington, D.C., 1965) pp. 169-176. |
| Rossi, A. B. R. et al. “Cellulite: a Review,” European Academy of Dermatology and Venercology, 2000, pp. 251-262, 12 pgs. |
| Rubinsky, B. “Principles of Low Temperature Cell Preservation,” Heart Failure Reviews, vol. 8, 2003, pp. 277-284. |
| Rubinsky, B. et al., “Cryosurgery: Advances in the Application of low Temperatures to Medicine,” International Journal of Refrigeration, vol. 14, Jul. 1991, pp. 190-199. |
| Saleh, K.Y. et al., “Two-Dimensional Ultrasound Phased Array Design for Tissue Ablation for Treatment of Benign Prostatic Hyperplasia,” International Journal of Hyperthermia, vol. 20, No. 1, Feb. 2004, pp. 7-31. |
| Schoning, P. et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology 27, 1990, pp. 189-193. |
| Shephard, R. J. “Adaptation to Exercise in the Cold,” Sports Medicine, vol. 2, 1985, pp. 59-71. |
| Sigma-Aldrich “Poly(ethylene glycol) and Poly(ethylene oxide),” http://www.sigmaaldrich.com/materials-science/materialscience-; products.htmi?TablePage=2020411 0, accessed Oct. 19, 2012. |
| Smalls, L. K. et al. “Quantitative Model of Cellulite: Three Dimensional Skin Surface Topography, Biophysical Characterization, and Relationship to Human Perception,” International Journal of Cosmetic Science, vol. 27, Issue 5, Oct. 2005, 17 pgs. |
| Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermaCool System,” Jun. 20, 2005, 2 pages. |
| Vallerand et al. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans,” Aviation, Space, and Environmental Medicine 70(1), 1999, pp. 42-50. |
| Wang, X. et al., “Cryopreservation of Cell/Hydrogel Constructs Based on a new Cell-Assembling Technique,” Sep. 5, 2009, 40 pages. |
| Wharton, D. A. et al., “Cold Acclimation and Cryoprotectants in a Freeze-Tolerant Antarctic Nematode, Panagrolaimus Davidi,”, Journal of Comparative Physiology, vol. 170, No. 4, Mar. 2000, 2 pages. |
| Winkler, C. et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” in Transgenic Animals, Generation and Use (The Netherlands 1997), pp. 387-395. |
| Young, H. E. et al. “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells” The Journal of Tissue Culture Methods, vol. 14, Issue 2, 1992, pp. 85-92. |
| Zouboulis, C. C. et al., “Current Developments and Uses of Cryosurgery in the Treatment of Keloids and Hypertrophic Scars,” Wound Repair and Regeneration, vol. 10, No. 2, 2002, pp. 98-102. |
| Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011. |
| Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180. |
| Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34. |
| Manstein, D. et al., “Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal”, 40 Lasers in Surgery & Medicine, 2008, pp. 595-604. |
| Zelickson, B. et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9. |
| Number | Date | Country | |
|---|---|---|---|
| 20140277219 A1 | Sep 2014 | US |
